

CURRICULUM VITAE

DATE: February 2021

NAME: Deborah Lynn Toppmeyer

PRESENT TITLE: Professor of Medicine,
Chief, Division of Medical Oncology
Chief Medical Officer
Director, The Stacy Goldstein Breast Center
Director, The Hereditary Oncology Prevention and Evaluation Program and
LIFE Center

OFFICE ADDRESS: Rutgers Cancer Institute of New Jersey
195 Little Albany Street
New Brunswick, NJ 08903

CITIZENSHIP: USA

EDUCATION:

- A. Undergraduate Graduate and Professional
Ohio Wesleyan University
Delaware, Ohio, USA
B.A. 05/1981

- B. Graduate and Professional
Albany Medical College
Albany, New York, USA
M.D. 05/1985
(Graduated on 05/24/85 and started internship on 06/24/85. Took vacation and moved
between medical school and internship)

POSTGRADUATE TRAINING:

- A. Internship and Residencies
University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
Intern in Medicine
07/1985-06/1986

University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
Junior Resident, Internal Medicine
07/1986-06/1987

University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
Senior Resident, Internal Medicine
07/1987-06/1988

- B. Research Fellowships
University of Pittsburgh School of Medicine
Physician Investigator Fellowship Training Program
07/1988-06/1990

Harvard Medical School, Boston, MA, USA
Clinical Fellow in Medicine
07/1990 – 7/1990

Dana-Farber Cancer Institute, Boston, MA, USA
Fellow in Medical Oncology
07/1990- 06/1994

Dana-Farber Cancer Institute
Special Fellow in the Breast Evaluation Center
07/1992-06/1993

Harvard Medical School and Harvard School of Public Health, Boston, MA
Summer Fellowship in The Program in Clinical Effectiveness, A Joint Program of
Brigham and Women's Hospital
07/1993 – 08/1993

C. Postdoctoral Appointments: N/A

D. Other:

Medical Staff Leadership Academy, Center for Executive Advancement, Robert Wood
Johnson University Hospital, New Brunswick, NJ
11/2015-05/2016

MILITARY: N/A

ACADEMIC APPOINTMENTS:

Division of Clinical Pharmacology
Dana-Farber Cancer Institute, Boston, MA, USA
Instructor in Medicine
07/1994-06/1995

Department of Medicine
UMDNJ/Robert Wood Johnson Medical School, New Brunswick, NJ, USA
Assistant Professor
07/1995-06/2002

Department of Medicine
UMDNJ/Robert Wood Johnson Medical School, New Brunswick, NJ, USA
Associate Professor
07/2002- 04/2004

Department of Medicine
UMDNJ/Robert Wood Johnson Medical School, New Brunswick, NJ, USA
Associate Professor with Tenure
04/2004- 03/2013

Division of Medical Oncology
Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ, USA
Section Chief, Solid Tumor Oncology
04/2010 – Present

Division of Medical Oncology
Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ, USA
Chief Medical Officer
09/2011 – Present

Department of Medicine
Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ, USA
Professor with Tenure

03/2013-Present

Division of Medical Oncology
Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ, USA
Chief, Division of Medical Oncology
03/2016– Present

HOSPITAL APPOINTMENTS:

Division of Clinical Pharmacology
Dana-Farber Cancer Institute, Boston, MA, USA
06/1994-06/1995

Medical Oncology, Department of Medicine
Robert Wood Johnson University Hospital, New Brunswick, NJ, USA
06/1995-06/2002

Medical Oncology, Department of Medicine
Robert Wood Johnson University Hospital, New Brunswick, NJ, USA
07/2002- 04/2004

Medical Oncology, Department of Medicine
Robert Wood Johnson University Hospital, New Brunswick, NJ, USA
04/2004- Present

OTHER EMPLOYMENT OR MAJOR VISITING APPOINTMENTS: N/A

PRIVATE PRACTICE: N/A

LICENSURE:

Medical License - State of New Jersey/25MA06310700/exp. 06/30/2021

DRUG LICENSURE:

CDS: D06799800 expiration date: 10/31/2020
DEA: BT0793237 expiration date: 11/30/2019

CERTIFICATION:

American Board of Internal Medicine, Board Certified in Oncology, Certificate
Expiration: 11/2027
American Board of Internal Medicine, #120524; expiration: Indefinite

MEMBERSHIPS, OFFICES AND COMMITTEE ASSIGNMENTS IN PROFESSIONAL SOCIETIES:

Alpha Omega Alpha
Member
1984-present

American College of Physicians
Associate Member
1986-present

American Medical Athletic Association
Member
1989-present

American Association for Cancer Research
Member

1992-present

American Society of Clinical Oncology
Member
1997-present

American Society of Breast Disease
Member
1998-present

HONORS AND AWARDS:

Chi Gamma Nu
National Honorary Chemistry Society
1979

Lubrizol Scholar in Chemistry
Ohio Wesleyan University
1980

Magna Cum Laude
Phi Beta Kappa
1981

Ralph Signet Award - for excellence in Chemistry Research
Ohio Wesleyan University
1981

Psi Chi
National Honorary Psychology Society
1981

Alpha Omega Alpha
National Honor Medical Society
1984

Spirit of Jane Rodney Award
Susan G. Komen Foundation
2005

Award of Hope for Leadership in Patient Care
Cancer Institute of New Jersey Foundation
2006

Night of Wine and Roses Medical Honoree
American Cancer Society
2010

Inside New Jersey Magazines' Top Doctors
Castle Connolly, American Registry
2002 - 2014

Castle Connolly Regional Top Doctor 2021, America Castle Connolly, Top 6% of all
U.S. board certified physicians - 2021

America's Most Honored Doctors - Top 1% of all recognized professionals in
America Castle Connolly, American Registry - 2020

America's Most Honored Professionals - Top 4% of all recognized professionals in America Castle Connolly, American Registry - 2011

America's Top Doctors for Cancer Care– Castle Connolly, American Registry: 2010 - 2020 (10th Anniversary)

Recognized as an Outstanding Leader, Making a Difference for Women Award
National Council for Research on Women
2012

America's Top Doctors - Castle Connolly Medical LTD – 13 yr. Anniversary
2014, 2016

America's Top Doctors 20 Years- Castle Connolly Medical LTD – 2020

America's Top Doctors: New York Metro Area - Castle Connolly Medical LTD 2000--
2020 (20th Anniversary)

Best Doctors in America – Top 5% of U.S. doctors - Best Doctors – 2014

Inside Jersey's Medical Oncology Top Doctor's for 2014 – Castle Connolly Medical
LTD. – 2014, 2015, 2016

Top Doctors For Cancer – Newsweek Magazine – 2015, 2016

Inside Jersey's Medical Oncology Top Doctor's for Women – Castle Connolly Medical
LTD. – 2016, 2017

America's Most Honored Professionals: Top 1% - The American Registry – 2016

Inside New Jersey Magazines' Top Doctors for Women's Health – pub; February 2017,
February 2018

Inside New Jersey Magazine: Top Doctors for Cancer Care – Inside Jersey – July 2017,
July 2018

2018 Woman of Distinction: Girl Scouts of Central and Southern New Jersey

Jersey' Best – Top Doctors for Cancer Care- June 2019, 2020

Exceptional Women in Medicine: Castle Connolly Top Doctors – 2019, 2020

BOARDS OF DIRECTORS/TRUSTEES POSITIONS: N/A

SERVICE ON NATIONAL GRANT REVIEW PANELS, STUDY SECTIONS, COMMITTEES:

1. Review Committee, Fox Chase Cancer Center's Keystone Programs, 2007-Present
2. Endocrine Therapies Scientific Peer Review Committee, Susan G. Komen for the Cure
2008-2010

SERVICE ON MAJOR COMMITTEES:

- A. International: N/A
- B. National:
 1. ASCO Advantage Educational Committee Co-Chair 2019
 2. ASCO: Peer Reviewer for the ASCO 2017 Annual meeting. 2017
 3. Oncothyreon ONT-380-206 Organizational Meeting (consultant), 2015
 4. Big Ten CRC Breast Clinical Trial Working Group, Co-chair, 2014-present

5. ASCO Cancer Education Committee, 2013-2015
 6. ASCO Scientific Program Committee, 2013 - 2015
 7. ASCO Triple Negative Breast Cancer Committee, 2012-Present
 8. American College of Radiology (“ACR”), Appropriateness Criteria Program -2012-Present
 9. ECOG Breast Committee, 2004-Present
 10. Breast Cancer Mini symposium AACR, 03/1998
- C. Medical School/University:
1. Rutgers Global Health Institute: Core Faculty member, 2019-present
 2. RCINJ Director Search Committee, 2016
 3. I2P2 Finance/Funds Flow Meeting, 2016
 4. I2P2 Steering Committee, 2015 -2016
 5. Department of Medicine Career Development Committee, 2015 - Present
 6. RU Health Readiness/Launch Steering Committee, 2015-present
 7. Member of the Institutional Review Board, Robert Wood Johnson Medical School/Robert Wood Johnson University Hospital, New Brunswick, New Jersey, 1998- 2003
- D. Hospital:
1. Patient Flow Steering Committee, Robert Wood Johnson University Hospital, New Brunswick, NJ 2016 – present
 2. Oncology Inpatient Length of Stay, Robert Wood Johnson University Hospital, New Brunswick, New Jersey, 2016- present.
 3. Career Development Committee, Robert Wood Johnson University Hospital, New Brunswick, New Jersey, 2014 – present
 4. Clinical Policy Subcommittee of the RBHS Ebola Preparedness Steering Committee, Robert Wood Johnson University Hospital, New Brunswick, New Jersey, 2014 – 2016.
 5. Joint Management Committee, RCINJ - RWJH, New Brunswick, New Jersey,
 6. System-wide Cancer Strategic Plan Committee, Robert Wood Johnson University Hospital, New Brunswick/Newark, New Jersey 2015 – Present
 7. Building Rutgers Health Committee, New Jersey 2015 – Present
 8. Board of Directors, Finance Committee, Robert Wood Johnson University Hospital, New Brunswick, New Jersey, 2013-2015
- E. Department
1. RCINJ/RWJBarnabas CNO Search Committee co-chair
 2. RCINJ Ambulatory Executive meeting
 3. RCINJ Recruitment Task Force Meeting, 2016-Present
 4. RCINJ Director Search Committee: 2015-2016
 5. RCINJ Clinical Operations Leadership Council, 2015 - 2017
 6. RCINJ Revenue Enhancement Council, 2013 - Present
 7. RCINJ Ambulatory Governing Council, 2012– Present
 8. RCINJ Appointments & Promotions Committee, 2012– Present
 9. RCINJ Executive Clinical IT and Applications Committee, 2012– Present
 10. Faculty Incentive Model Committee, 2010 – Present
 11. RCINJ Executive Committee, 2008 – Present
 12. RCINJ Clinical Operations Executive Committee, 2010 – Present
 13. RCINJ Operations Committee, 2010 – 2012
 14. RCINJ Director’s Council, 1998 -- 2000
- F. Editorial Boards
1. Clinical Cancer Research, 2007 – Present
- G. AdHoc Reviewer
1. New England Journal of Medicine: 2019 - Present
 2. JCO, 2007 – Present
 3. The Journal of Breast Cancer Research and Treatment, 2007 – Present
 4. JCO Precision Oncology, 2019-present

SERVICE ON GRADUATE SCHOOL COMMITTEES:

1. Leader; CINJ Breast Tumor Study Group, 1998 – Present
2. Member, Fellowship Core Selection Committee, 2006- Present
3. Elections and Nomination Committee, UMDNJ-Robert Wood Johnson Medical School, 2006- Present
4. Member, Hearing Body for Student Rights, UMDNJ-Robert Wood Johnson Medical School, 2008- Present
5. Member, Department of Medicine Career Development Committee, 2010- Present,

SERVICE ON HOSPITAL COMMITTEES:

1. Board of Directors, Finance Committee, Robert Wood Johnson University Hospital, New Brunswick, New Jersey, 2013-2015
2. Chair, CINJ EMR Steering Committee, 2010 – Present
3. Member, Joint Management Council CINJ/Robert Wood Johnson University Hospital, 2010 -- Present

SERVICE TO THE COMMUNITY:

1. Invited speaker (expert), Atlantic Health System Cancer Care: 2020 Annual review in Oncology Virtual Symposium. Virtual Format via Skype. June 27, 2020.
2. Invited as panel expert, Association for Value-Based Cancer Care (AVBCC), Cancer Care Behavior Management Program to Increase Human Resiliency to Stay on Therapy and Achieve Quality Measures While Reducing Clinical Fatigue, New York, NY. October 19, 2019
3. Invited speaker, Girl Scout Leadership Summit, Why I Became a Medical Oncologist: Breast Cancer, Rowan College, Mt. Laurel, NJ. December 2018
4. Invited speaker, Breast Cancer Symposium 2017, CME event. Options for Current Treatment and management of Advanced Breast Cancer in geriatric Population. CMC, Toms River, NJ. October 17, 2017
5. Invited speaker, Patient Symposium, Living with Metastatic Breast Cancer, RCINJ, New Brunswick, NJ October 10, 2017
6. Invited speaker, Why Do You Do What You Do? How Did You Get There, Discovery Education Summer STEMMersion, Charlotte, NC, 7/24/2017
7. Invited to serve as expert: US Breast Cancer Expert Input Forum: Dallas, Texas, January 21, 2017
8. Cancer Support Committee: Moonshot Summit: June 29th – Panel participant, Bedminster, NJ, July 29, 2016
9. Invited Speaker, Overlook Medical Center, Summit, NJ, 10/16/2015
10. Invited Speaker, along with Val Skinner Foundation: “BioCONNECT/BOLD” project, Orlando, FL, Sept. 14-16, 2014.
11. Invited Speaker, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, 06/08/2014.
12. Invited Speaker, “BioCONNECT”, WWE, Stamford, CT., 05/06/2014
13. Invited Speaker, Shore Medical center Tumor Board, Somers Point, NJ, 11/22/2014
14. Invited Speaker, “Expert Insights on the Latest Evidence in Metastatic Breast Cancer”, West Palm Beach, FL, 11/06/2013
15. Invited Speaker, Athleta, “Breast Cancer Myths vs. Reality”, Princeton, NJ, 10/22/2013
16. Life Event, 2013, Princeton, NJ, 06/10/2013
17. Invited Speaker, First National Triple Negative Breast Cancer Awareness Day, YWCA Princeton, NJ, 03/01/2013
18. Invited Speaker, Stitch Fore Time Lunch and Learn, “Breast Cancer”, Deal, NJ, 10/17/2012.
19. Invited Speaker, BJ’s Pink Picnic, Edison, NJ, 10/10/2012
20. Invited Speaker/participant, Life Event 2013, Val Skinner Foundation, West Caldwell, NJ, 07/11/2012
21. Invited Speaker, Emblem Health Wear Pink Day. “Breast Health”, New York, NY, 11/2011

22. Invited Speaker, “Advances, Breakthroughs, and Controversies in Breast Cancer Treatment Trials and the Future of Currently Used Agents,” VA NJ Healthcare Systems, East Orange, NJ, 10/2011
23. Invited Speaker, Genetic Counseling: Identify Your Risks for hereditary Cancer. UMCP Breast Health Center, East Windsor, NJ, 10/2011
24. Invited Speaker, BJ’s Pink Picnic, Edison, NJ, 10/2011
25. Organized/supported the Cancer Symposium for BRCA1 & BRCA2 gene carriers, “Current Issues in Hereditary Breast & Ovarian Cancer”, Cancer Institute of New Jersey, New Brunswick, NJ, 09/2011
26. Organized/supported the BOLD Initiative, BioConect Oncology Leadership Development camp for high school students, Cancer Institute of New Jersey, New Brunswick, NJ, 07/2011
27. Invited Speaker, Living Beyond Breast Cancer Networking Meeting, “Metastatic Breast Cancer: Understanding Your Treatment Options”, Cherry Hill, NJ, 06/2011
28. Invited Speaker, CINJ Survivor’s Day” Vitamin D and Calcium: Not for Women Only”, Cancer Institute of New Jersey, New Brunswick, NJ, 06/2011
29. Life Event 2011, South Hampton, NY, 06/2011
30. Co-chair Capital Campaign, Nassau Presbyterian Church, Princeton, NJ, 05/2011- Present
31. Deacon - Nassau Presbyterian Church, Princeton, NJ, 03/2010-Present
32. Invited Speaker, Living Beyond Breast Cancer’s Annual Fall Conference, “Triple-Negative Breast Cancer: Medical and Lifestyle Update”, Philadelphia, PA, 11/2010
33. Invited Speaker, Breast Conference – CINJ Network Program, Morristown, NJ, 11/2010
34. Invited Speaker, The Wellness Community of Central NJ, “Advanced Breast Cancer”, Bedminster, NJ, 10/2010
35. Invited Speaker, BJ’s Pink Picnic, Edison, NJ, 10/2010
36. Invited Speaker, Breast Conference – CINJ Network Program, Princeton, NJ, 10/2010
37. Invited Speaker, Novartis Program, “Adjuvant Therapy for Early Breast Cancer”, Newton, PA, 09/2009
38. Invited Speaker, American Cancer Society-Making Strides Against Breast Cancer, Iselin, NJ, 08/2009
39. Invited Speaker, New Jersey Cancer Survivorship Conference, “Medical Management Issues in Cancer Survivorship”, Mount Laurel, NJ, 11/2008
40. Invited Speaker, “Improving Patient Outcomes: Maximizing New and Existing Treatment Options”, Oncology Registrar Association of NJ Annual Meeting, Atlantic City, 10/2008
41. Invited Speaker, Lunch and Learn on behalf of the Val Skinner Foundation, NY, NY, 10/2008
42. Invited Speaker, “What is Triple Negative Breast Cancer, Triple Negative Breast Cancer Foundation – Saks Fifth Avenue Fundraiser, The Shops at Riverside Mall, Hackensack, NJ., 02/2008
43. Invited Speaker, “The Latest in Treatment for Breast Cancer”, Tied to the Cause: Recent Advances in Breast Cancer Diagnosis and Treatment, Robert Wood Johnson University Hospital, New Brunswick, NJ, 10/2007
44. Invited Speaker, “New Treatments for Women Living with Advanced Breast Cancer”, Hope on the Horizon: Living Beyond Breast Cancer’s Stacy Goldstein Symposium on Breast Cancer. Somerset, NJ, 10/ 2004
45. Invited Speaker, “Hope on the Horizon: New Treatment Options for Women With Advanced Breast Cancer”, 4th Annual Conference for Young Women Affected by Breast Cancer, Young Survival Coalition, Philadelphia, PA, 02/ 2004
46. Invited Speaker, NJHA (New Jersey Hospital Association), "Breast Cancer Epidemiology, Early Detection and Prevention". Princeton, NJ. (Toppmeyer), 06/24/2003
47. Invited Speaker, Aventis Oncology, Grand Rounds at Bayshore Hospital, "The Role of Taxanes in Metastatic Breast Cancer". Holmdel, NJ, 03/14/2003
48. Invited Lecturer for UMDNJ Center for Continuing and Outreach Education. Spoke at Ortho-McNeil Pharmaceuticals, Grand Rounds, "Update on Breast Cancer". Raritan, NJ, 11/13/2002
49. Presented at Saint James Hospital, Continuing Medical Education Conference, Grand Rounds, “Cancer Genetics”, Newark, NJ, 09/25/2002
50. OSCE at Saint Peter’s University Medical Center, New Brunswick, NJ, 12/05/2001
51. Invited Speaker, Overlook Hospital, Summit, NJ, “Potpourri for Practicing Physicians”. Topic: Cancer Genetics for the Health Care Professional”, 10/31/2001

52. Invited Speaker, “Breast Cancer – Quality of Life”. WMGQ – WCTC hosting, “Life Event”, Somerset, NJ. Call in Radio program, 07/20/2001
53. Invited Speaker, “Breast Cancer – Quality of Life”. WMGQ – WCTC hosting, “Life Event”, Somerset, NJ. Call in Radio program, 06/20/2001
54. Invited guest, CINJ Representative, for the Annual Friends of Mountainside, Hospital Recognition Reception. Essex Fells Country Club, Essex Falls, NJ, 06/06/2001
55. Invited Speaker, “STAR Trial – Breast Cancer Prevention”, Honeywell Headquarters, Morris Township, NJ, 05/31/2001
56. Presented two posters at the ASCO 2001 Annual Meeting. San Francisco, CA, 05/09/2001
57. Gave a presentation at the CINJ Annual Retreat. Princeton, NJ. See Abstract, 04/25/2001
58. Invited Speaker, “Basic Cancer Genetics for Healthcare Providers: Risks and Realities”. 2nd Annual New Jersey Physicians Conference, Atlantic City, NJ, 04/20/2001
59. Invited Speaker, “Advances in the Treatment of Metastatic Breast Cancer. Cirque Du Soliel’s, Liberty State Park, Jersey City, NJ. (Aventis Oncology), 04/18/2001
60. Press Event, Update on Women’s Cancers, CINJ. Topic: “Familial Breast Cancer & Chemoprevention Strategies, 04/11/2001
61. Grand Rounds, The Medical Center At Princeton. Topic: “Cancer Genetics: Risk and Assessment”, 04/03/2001
62. Tumor Board, UMDNJ Newark. Topic: “Femara-Hormonal Therapy”, 03/19/2001
63. Didactic Lecture – “Cancer Genetics for the Health Care Professional”. Vineland Developmental Center, Vineland, NJ, 03/12/2001
64. Participated at the Clinical Investigators Retreat. CINJ, 03/10/2001
65. Grand Rounds Presenter at Somerset Medical Center. Topic: Genetic Testing for Breast, Ovarian and Colon Cancer, 03/01/2001
66. Invited to participate on Congressman Rush Holt’s Advisory Panel. Meeting was held in Princeton Junction, NJ, 02/24/2001
67. Lecture at ECOG Meeting at Mountainside Hospital. Topic: “ECOG Update and Breast Cancer”, 02/14/2001
68. Lecture at the Clinical Staff Conference, Mountainside Hospital. Topic: “Cancer Genetics and Risk Management.”, 02/13/2001
69. Invited Speaker, “The Importance of Prevention and Early Detection,” at the Molly Pitcher Inn, Red Bank, NJ. Sponsored by the American Cancer Society, 02/08/2001
70. Invited Speaker, “Cancer Genetics – Who is at Risk”. Princeton United Jewish Federation, 01/24/2001
71. Lecture “Genetics The Future is Now”. 2nd year medical students, Main Lecture Hall, RWJMS, Piscataway, NJ, 12/13/2000
72. Princeton Medical Center Tumor Board. Topic: Hormonal Therapy”, 12/11/2000
73. Friday Morning Conference, CINJ. Presented: “Update on The Breast Tumor Study Group”, 10/05/2000
74. Interview, five minute segment, Comcast Newsmakers, Trenton, NJ. “Early detection, Advancements in hormonal treatment for breast cancer”. 08/23/2000
75. Invited Speaker, “Chemoprevention and Breast Cancer – The STAR Trial. Dinner meeting at the Frog & The Peach, New Brunswick, NJ. (Sponsored by Amgen), 11/29/2000
76. Participated as a panel member at the talk back session at WIT, a play presented at the George Street Playhouse, 11/09/2000
77. Invited speaker at Novartis in East Hanover, NJ. “Breast Cancer Adjuvant Therapy”, 08/31/2000
78. Participated in the Summit Action Planning Committee, sponsored by the State of New Jersey Commission on Cancer Research, held at the Department of Health and Senior Services, Trenton, NJ, 07/25/2000
79. Presentation of the STAR trial for the CINJ Board of Directors, 11/08/1999
80. Discussed the STAR trial Mayor’s Lunch and Learn for New Brunswick Employees, 10/21/1999
81. Race for the Cure Press Conference, 08/1999
82. Medical Grand Rounds Raritan Bay Hospital overview of the Star Trial CME, 06/22/1999
83. Centrastate STAR Presentation, 06/18/1999
84. Centrastate STAR Presentation (Study of Tamoxifen and Raloxifene), 06/11/1999

85. Radio Interview Michele Fischer WCTC re STAR trial, 06/16/1999
86. Press Conference highlighting the STAR Trial, 05/25/1999
87. Panelist "Breast Health in the News: How to be an Educated Consumer" Cosponsored by The Cancer Institute of New Jersey and Jewish Family and Vocational Service of Middlesex County, 02/02/1999
88. Catholic Daughters of America: Topic "Overview of Risk Factors and Breast Cancer Prevention Trial", 01/19/1999
89. Invited speaker at the American Society of Health-System Pharmacists: Topic "Practical Genetics for the Pharmacist" Las Vegas, Nevada CME, 12/10/1998
90. Robert Wood Johnson Tumor Board- Moderator CME, 12/07/1998
91. Raritan Bay Medical Center breakfast program symposium Topic "Cancer Genetics: Risk and Assessment" CME, 11/18/1998
92. Jersey Shore Medical Center "Molecular Basis of Hypercalcemia of Malignancy" Novartis sponsored presentation CME, 11/04/1998
93. Longaberger Horizon of Hope Event-- Annual National Charity Campaign benefiting the ACS: Topic "Familial Breast Cancer", 10/24/1998
94. NBC The Today Show -Weekend: Topic "Tam Prevention Trial, 10/17/1998
95. News 12 NJ: Topic: "Early-onset breast cancer", 10/16/1998
96. Breast Cancer Awareness Lecture at Merck: Topic: "Overview of the Tamoxifen Prevention Trial", 10/07/1998
97. ACS Morris County Division Meeting: Topic: "What's New in Breast Cancer", 10/05/1998
98. Family Practice Grands Rounds St. Peter's Medical Center: Topic: "Cancer and Screening", 09/11/1998
99. News 12 NJN: Topic: "Tamoxifen Prevention Trial", 09/02/1998
100. ACS Princeton Division Meeting: Topic: "Clinical Trials in Breast Cancer", 08/1998
101. Caucus: New Jersey's "Informed Choices" a panel discussion lead by Steve Aduato "Is It All in the Genes", 08/18/1998
102. Longaberger Horizon of Hope Event-- Annual National Charity Campaign benefiting the ACS: Topic "Familial Breast Cancer", 08/15/1998
103. NJN Interview: Topic: "Genetics of Cancer", 07/21/1998
104. Robert Wood Johnson - Medical Grand Rounds "Familial Breast and Ovarian Cancer", 06/17/1998
105. Lunch and Learn @ St. Peter's Medical Center: Topic: "Familial Breast and Ovarian Cancer, 05/07/1998
106. Fox 5 Interview: Topic: Farnesyl Transferase Inhibitor", NY, NY, 05/02/1998
107. Community Lecture, "Town Meeting", Morristown Memorial Hospital "Familial Cancer", 04/30/1998
108. Cable Channel CN8 "Family Talk" Live 1 hr Interview- Topic: Tamoxifen and Breast Cancer, 04/14/1998
109. Star Ledger Interview (Page 1): Topic: "The Tamoxifen Prevention Trial", 04/07/1998
110. Educational Program at Overlook Hospital "Potpourri for Practicing Physicians": Topic: "Genetic Screening for Breast Cancer", 03/04/1998
111. Educational Forum at Raritan Bay "What's New in Oncology": Topic: "Cancer Genetics", 11/03/1997
112. Breast Cancer Awareness Lecture at Johnson and Johnson: Topic: "Breast Cancer Risk Factors", 10/30/1997
113. Women's Health Forum: "Women's Cancers- Risks and Realities", 09/11/1997
114. Educational Program "Breast Cancer In the Next Mellenium: A Comprehensive Forum" Morristown Memorial Hospital: Topic: "Understanding Familial Breast Cancer: Who Is at Risk?", 09/10/1997
115. Presentation - St. Gregory's Greek Orthodox Church - "Risk Factors and Breast Cancer Screening - Highland Park, 11/20/1996
116. Rahway Hospital - Breast Health Forum Presentation - "Breast Cancer Risk Factors and Screening" - Rahway, NJ, 09/29/1996
117. Presentation to support Group "Coping with Cancer" - New Brunswick, 06/05/1996
118. TV Talk Show Updates in Breast Cancer - Philadelphia, 06/04/1996

SPONSORSHIP (Primary Mentorship) OF CANDIDATES FOR POSTGRADUATE DEGREE:
N/A

SPONSORSHIP (Primary Mentorship) OF POSTDOCTORAL FELLOWS:

1995-2012, Mentorship of Fellows in six month continuity clinics. 4 hrs. /wk, 208 hrs. /yr.

TEACHING RESPONSIBILITIES:

A. Lectures or Course Directorships

1. Imedex, LLC and University of Nebraska Medical Center Grand Rounds, Emerging Treatment Strategies for Advances and Metastatic ER+ Breast Cancer: The Clinical Potential of CDK 4/6 Inhibitors. CarePoint health Christ Hospital, Jersey City, NJ. April 7, 2017.
2. OB Grand Rounds, Rutgers Cancer Institute of New Jersey. "Beyond BRCA 1 & 2: Clinical Implications of Multi-gene Testing for Hereditary Cancers: October 14, 2015. 1 hr.
3. American College of Physicians, ACP, New Jersey Chapter, "Advances in Cancer Treatment for General Internists: Breast and Colon Cancer", March 6, 2015.
4. Rutgers/Cancer Institute of New Jersey/School of Public Health, BioCONNECT, BOLD High School Summer Camp: High school integrated curriculum supplement that enhances learning by encouraging students to transfer their knowledge of biology and genetics to real-life situations using breast cancer as the context as well as introduces students to diverse health-related careers. Developer and Invited Lecturer. July 22 – 26, 2014, 12 – 15 hrs./yr.
5. Rutgers/Cancer Institute of New Jersey/School of Public Health, BioCONNECT, BOLD High School Summer Camp: High school integrated curriculum supplement that enhances learning by encouraging students to transfer their knowledge of biology and genetics to real-life situations using breast cancer as the context as well as introduces students to diverse health-related careers. Developer and Invited Lecturer. July 22 – 26, 2013, 12 – 15 hrs./yr.
6. UMDNJ/CINJ/School of Public Health, BioCONNECT, BOLD High School Summer Camp: High school integrated curriculum supplement that enhances learning by encouraging students to transfer their knowledge of biology and genetics to real-life situations using breast cancer as the context as well as introduces students to diverse health-related careers. Developer and Invited Lecturer. July 23 – 27, 2012, 12 – 15 hrs./yr.
7. UMDNJ/CINJ/School of Public Health, BioCONNECT, BOLD High School Summer Camp: High school integrated curriculum supplement that enhances learning by encouraging students to transfer their knowledge of biology and genetics to real-life situations using breast cancer as the context as well as introduces students to diverse health-related careers. Developer and Invited Lecturer. July 25 – 29, 2011, 12 – 15 hrs./yr.
8. Dr. Carver at Robert Wood Johnson University Medical School medical students, "How to Deliver Bad News", April 22, 2003, 1 hr.
9. Robert Wood Johnson Medical School Residents, "Breast Cancer: Staging and Treatment". February 18, 2003, 1hr.
10. Robert Wood Johnson Medical School, UMDNJ Physician Assistant Program, Clinical Medicine Lecture Series, "Cancer Genetics", November 15, 2002, 1 hr.
11. Robert Wood Johnson Medical School, "Genetics The Future is Now", 2nd year medical students, December 13, 2000, 1hr.
12. Ohio Wesleyan University, Introduction to Clinical Medicine for Dental Residents, Lecturer for a 1 week course, 8-12 residents, 1978-1980, 10 h/year
13. Ohio Wesleyan University, Introduction to Chemistry, Undergraduate Laboratory Instructor, 4h/week junior and senior year. 1978-1980, 20 hrs. /yr.
14. Dana-Farber Cancer Institute, "Clinical Preceptor", First Year Oncology Fellows. 1991, 4 hrs. /wk, 208 hrs. /yr.
15. Harvard Medical School, Tutor in "Principles in Pharmacology", 1995, 10 hrs.

16. Robert Wood Johnson Medical School, Resident lectures, 1-2 per year, "Overview of the Management of Breast Cancer" and "Familial Breast and Ovarian Cancer", 1995-2012, 2 hrs./yr.

B. Research Training – N/A

CLINICAL RESPONSIBILITIES:

1. Medical Director of the Harvard Phase I Oncology Group, Dana-Farber Cancer Institute, Boston, MA, 1993-1995
2. Breast Evaluation Center Attending Physician, Dana-Farber Cancer Institute, Boston, MA, 1994-1995
3. Member of the Human Protection Committee, Dana-Farber Cancer Institute, Boston, MA, 1994-1995
4. General Medicine and Oncology Attending Physician, Robert Wood Johnson University Hospital at UMDNJ, New Brunswick, New Jersey, 1995-Present
5. Director of the Hereditary Oncology Prevention and Evaluation Program, The LIFE Program, The Cancer Institute of New Jersey, New Brunswick, New Jersey, 1997-Present
6. Director of The New Jersey Comprehensive Breast Care Center, The Cancer Institute of New Jersey, New Brunswick, New Jersey, 1998-Present
7. Section Chief, Solid Tumor Oncology, 2010- 04/2016
8. Chief, Division of Medical Oncology, 04/2016 – present
9. Chief Medical Officer, CINJ, 2011-Present

GRANT SUPPORT:

A. Principal Investigator

1. Robert Wood Johnson University Hospital, "CINJ Breast Cancer Research and Development Funds Award" 562179, 2005-2006, \$5,000.
2. Susan G. Komen Breast Cancer Foundation Central and South Jersey Affiliate, "CINJ High School Breast Cancer Education and Outreach Program" 2007-2008, \$50,000
3. George A. Ohl, Jr. Cancer Foundation, "Is the Newly Discovered SNP309 a Genetic Marker for early-age onset of Breast Cancer?" 2004-2009, \$47,758
4. CINJ, Breast Cancer Research Development Funds Award "The Impact of a Single Nucleotide Polymorphism in the Mdm2 Gene, SNP309, on Age at Breast Cancer Diagnosis and Time to Recurrence" 2004-2005, \$25,000
5. CINJ, Collaborative Research Award "Study of a Novel Breast Cancer Chemotherapy Strategy: Activation of Autophagy in Beclin 1 +/- Tumors" 2004-2005, \$27,500
6. R01CA95275-01 NIH/NCI, Phase II Doxorubicin/ Vinorelbine in wtp53 Breast Cancer 2003-2008 \$791,854
7. CINJ, Collaborative Research Award The Impact of A Relative's Mammogram: A "Teachable Moment"? 2003-2004, \$40,000
8. CINJ, Breast Cancer Collaborative Research Award Tamoxifen/Raloxifen and Trait Negative Affect, 2000-2001, \$25,000
9. R25-CA79924-01 NIH/NCI, Cancer Genetics Education for Health Care Professionals, 1999-2004, \$789,092 (total)
10. R21 CA8207-01 NIH/NCI, Sequential Doxorubicin and Vinorelbine in Breast Cancer, 1999-2002, \$155,909

CLINICAL TRIALS:

A. Principal Investigator

1. Novartis Pharmaceuticals, SOLAR-1: A phase III randomized double-blind, placebo controlled study of alpelisib in combination with fulvestrant for men and postmenopausal women with hormone receptor positive, HER2-negative advanced breast cancer which progressed on or after aromatase inhibitor treatment, 11/11/2015 open, \$14,980.00 (Total Direct and Indirect).

2. Merck, A Phase II Clinical Trial of Pembrolizumab as Monotherapy for Metastatic Triple-Negative Breast Cancer (mTNBC), 07/15/2015 open, \$70,046.22 (Total Direct and Indirect).
3. NSABP B-55: A Randomised, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy, 04/22/2015, open to accrual.
4. Genetech/J&J, DOXILBCA2010: AVF3879s: (NJ 2107) A Phase II Trial of Doxil , Carboplatin and Bevacizumab in Triple Negative Previously Untreated Metastatic Breast Cancer. A study of The Cancer Institute of New Jersey Oncology Group (CINJOG), 05/2007-12/31/2012, \$65,689.60 (Total Direct).
5. Novartis, Phase I/II Study of Weekly Abraxane and RAD001 in Women with Locally Advanced or Metastatic Breast Cancer. A Study of the Cancer Institute of New Jersey Oncology Group (CINJOG), 03/1/2009 – 12/31/2015, \$106,836.00.
6. Hoffman LaRoche, BO22589/TDM4788: A randomized, 3 arm, multicentre, phase III study to evaluate the efficacy and the safety of T-DM1 combined with pertuzumab or T-DM1 combined with pertuzumab-placebo (blinded for pertuzumab), versus the combination of trastuzumab plus taxane, as first line treatment in HER2- positive progressive or recurrent locally advanced or metastatic breast cancer (MBC), 08/01/2010 - 10/21/2013, \$19,341 (Total Direct).
7. Abbott, A Randomized Phase 2 Study of the Efficacy and Tolerability of Veliparib in Combination with Temozolomide or Veliparib in Combination with Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Subjects with BRCA1 or BRCA2 Mutation and Metastatic Breast Cancer, 05/24/2012 – 5/23/2013), \$9,884.62.
8. Novartis, An Open-Label Phase IIa Trial Evaluating the Safety and Efficacy of EPO906 (Epothilone B) in Patients with Advanced Breast Cancer (EPO906A2205), 10/01/2001 – 09/30/2010, \$83,768.00 (Total Direct)
9. Novartis, A phase Ib/IIa trial of LBH589 in combination with trastuzumab in adult female patients with HER2-positive metastatic breast cancer whose disease has progressed during or following treatment with trastuzumab, 10/18/2007 – 06/15/2010, \$14,095.00 (Total Direct).

GRANT SUPPORT:

B. Co-Investigator

1. A1 R01 CA233662-01A1 Evolution and clinical impact of clonal hematopoiesis of indeterminate potential in breast tumor microenvironment. 07/01/19-06/30/2024. PI: Hossein Khiabani. Total Direct Cost Year 1: 05/01/2019 – 04/30/2020 - 642,911 Total Direct Cost: 05/1/2019-4/30/2024 - 3,214,554.00
2. CA122795-01 NIH/NCI, "LOH at BRCA1/BRCA2 Loci as a Precursor to Breast Tumorigenesis". 2009-2012, \$372,896. PI: Mark Brenneman.
3. Eastern Cooperative Oncology Group, Participation in Eastern Cooperative Oncology Group, 06/15/2010 – 04/30/2016, \$435,943. PI: J. Aisner.
4. Ruth Estrin Goldberg Memorial for Cancer Research, Role of Genetic Variants in the mTOR Pathway on Breast Cancer Outcomes. 07/01/2009 – 06/30/2010, \$6,000. PI: Kim Hirshfield.
5. NJCCR, Computational and Systems Biology-Enhanced Molecular Epidemiology Network 2009-2010, \$489,288 . PI: Arnold J. Levine.
6. NJCCR Epithelial Integrity in Breast Cancer Recurrence. 07/01/2008-06/30/2012, \$120,000, PI: Kim Hirshfield
7. 5P30 CA072720 NIH/NCI Cancer Center Support Grant Program, Co-Program Leader, Breast Cancer Research Program, 2004-2011. \$2,074,597. PI: R. DiPaola.

PUBLICATIONS:

- A. Refereed Original Article in Journal

1. **Toppmeyer DL**, Press MF. Testing considerations for phosphatidylinositol-3-kinase catalytic subunit alpha as an emerging biomarker in advanced breast cancer. *Cancer Med.* 2020;00:1–10. <https://doi.org/10.1002/cam4.3278>. 10 June 2020
2. Manish R.Sharma,MD1*,Shailly Mehrotra,PhD2*,Elizabeth Gray,MS1,Kehua Wu, PhD1, William T. Barry, PhD3, Clifford Hudis, MD4, Eric P. Winer, MD5, Alan P. Lyss, MD6, **Deborah L. Toppmeyer**, MD7, Alvaro Moreno-Aspitia, MD8,Thomas E. Lad, MD9, Mario Velasco, MD10, Beth Overmoyer, MD5, Hope S. Rugo, MD11, Mark J. Ratain, MD1, and Jogarao V. Gobburu, PhD2. “Personalized Management of Chemotherapy-Induced Peripheral Neuropathy Based on a Patient Reported Outcome: CALGB 40502 (Alliance).” *The Journal of Clinical Pharmacology* 2020, 60(4) 444–452. C 2019, The American College of Clinical Pharmacology. DOI: 10.1002/jcph.1559
3. Karam R, Conner B, LaDuca H, McGoldrick K, Krempely K, Richardson ME, Zimmermann H, Gutierrez S, Reineke P, Hoang L, Allen K, Yussuf A, Farber-Katz S, Rana H, Culver S, Lee J, Nashed S, **Toppmeyer D**, Collins D, Haynes G, Pesaran T, Dolinsky JS, Tippin Davis B, Elliott A, Chao E. “Assessment of Diagnostic Outcomes of RNA Genetic Testing for Hereditary Cancer”. *JAMA Netw Open*. 2019 Oct 2;2(10):e1913900. doi: 10.1001/jamanetworkopen.2019.13900.
4. Sparano JA, Gray RJ, Makower DF, Albain KS, Saphner TJ, Badve S, Wagner LI, Kaklamani VG, Keane MM, Gomez HL, Reddy PS, Goggins T, Mayer, **Toppmeyer DL**, Brufsky AM, Goetz MP, Berenberg JL, Mahalcioiu C, Desbiens C, Hayes DF, Dees EC, Geyer CE Jr, Olson JA Jr, Wood WC, Lively T, Paik S, Ellis MJ, Abrams J, Sledge GW Jr, “Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical Trial” *JAMA Oncol*. 2019 Sep 30. doi: 10.1001/jamaoncol.2019.4794.
5. Gupta A, Khan AJ, Yegya-Raman N, Sayan M, Ahlawat S, Ohri N, Goyal S, Moore DF, Eladoumikdachi F, **Toppmeyer D**, Haffty BG. “Five-Year Results of a Prospective Phase 2 Trial Evaluating Three-Week Hypofractionated Whole Breast Radiotherapy Inclusive of a Sequential Boost”. *Int J Radiat Oncol Biol Phys*. 2019 Jun 5. pii: S0360-3016(19)30817-X. doi: 10.1016/j.ijrobp.2019.05.063. [Epub ahead of print]PMID: 31175905
6. Sparano JA, Gray RJ, Ravdin PM, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Goetz MP, Olson JA Jr, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Berenberg JL, Abrams J, Sledge GW Jr “Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer.” *N Engl J Med*. 2019 Jun 20;380(25):2395-2405. doi: 10.1056/NEJMoa1904819. Epub 2019 Jun 3.PMID: 31157962
7. Manne S, Smith B, Mitarotondo A, Frederick S, Toppmeyer D, Kirstein L. Decisional conflict among breast cancer patients considering contralateral prophylactic mastectomy.*Patient Educ Couns*. 2019 May;102(5):902-908. doi: 10.1016/j.pec.2018.12.008. Epub 2018 Dec 10
8. Rashkin SR, Chua KC, Ho C, Mulkey F, Jiang C, Mushiroda T, Kubo M, Friedman PN, Rugo HS, McLeod HL, Ratain MJ, Castillos F, Naughton M, Overmoyer B, Toppmeyer D, Witte JS, Owzar K, Kroetz DL. A Pharmacogenetic Prediction Model of Progression-Free Survival in Breast Cancer using Genome-Wide Genotyping Data from CALGB 40502 (Alliance). *Clin Pharmacol Ther*. 2019 Mar;105(3):738-745. doi: 10.1002/cpt.1241. Epub 2018 Nov 1.PMID: 30260474
9. Khiabani H, Hirshfield KM, Goldfinger M, Bird S, Stein M, Aisner J, Toppmeyer D, Wong S, Chan N, Dhar K, Gheeya J, Vig H, Hadigol M, Pavlick D, Ansari S, Ali S, Xia B, Rodriguez-Rodriguez L, Ganesan S. “Inference of Germline Mutational Status and Evaluation of Loss of Heterozygosity in High-Depth, Tumor-Only Sequencing Data.” *JCO Precis Oncol*. 2018;2018. doi: 10.1200/PO.17.00148. Epub 2018 Jan 19.PMID: 30246169
10. Adams S, Schmid P, Rugo HS, Winer EP, Loirat D, Awada A, Cescon DW, Iwata H, Campone M, Nanda R, Hui R, Curigliano G, Toppmeyer D, O’Shaughnessy J, Loi S, Paluch-Shimon S, Tan AR, Card D, Zhao J, Karantzis V, Cortés J. “Pembrolizumab

- Monotherapy for Previously Treated Metastatic Triple-Negative Breast Cancer: Cohort A of the Phase 2 KEYNOTE-086 Study” *Ann Oncol.* 2018 Nov 26. doi: 10.1093/annonc/mdy517. PMID: 30475950
11. Suzette Farber-Katz, Vickie Hsuan, Sitao Wu, Tyler Landrith, Huy Vuong, Dong X, Bing Li, Jayne Hoo, Stephanie Lam, Sarah Nashed, Deborah Toppmeyer, Phillip Gray, Ginger Haynes, Hsiao-Mei Lu, Aaron Elliott, Brigitte Tippin Davis and Rachid Karam, “Quantitative Analysis of BRCA1 and BRCA2 Germline Splicing Variants Using a Novel RNA-Massively Parallel Sequencing Assay” *Front. Oncol.*, 27 July 2018.
 12. Toppmeyer, DL, (Collaborator), Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. *N Engl J Med.* 2018 Jul 12;379(2):122-137. doi: 10.1056/NEJMoa1803164. Epub 2018 Jun 4.
 13. Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Goetz MP, Olson JA Jr, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Ravdin PM, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Berenberg JL, Abrams J, Sledge GW Jr. Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. *N Engl J Med.* 2018 Jul 12;379(2):111-121. doi: 10.1056/NEJMoa1804710. Epub 2018 Jun 3. PMID: 29860917
 14. Arlow RL, Paddock LE, Niu X, Kirstein L, Haffty BG, Goyal S, Kearney T, Toppmeyer D, Stroup AM, Khan AJ. Breast-conservation Therapy After Neoadjuvant Chemotherapy Does Not Compromise 10-Year Breast Cancer-specific Mortality. *Am J Clin Oncol.* 2018 May 18. PMID: 29782362
 15. Khan AJ, Poppe MM, Goyal S, Kokeny KE, Kearney T, Kirstein L, Toppmeyer D, Moore DF, Chen C, Gaffney DK, Haffty BG. “Hypofractionated Postmastectomy Radiation Therapy Is Safe and Effective: First Results From a Prospective Phase II Trial.” *J Clin Oncol.* 2017 Jun 20;35(18):2037-2043. doi: 0.1200/JCO.2016.70.7158. Epub 2017 May 1. PMID: 28459606
 16. Sparano J., Gray R, Makower D, Pritchard K, Albain K, Hayes D, Geyer Charles Jr., Dees E, Perez E, Olson John Jr., Zujewski J, Keane M, Gomez Moreno H, Reddy P, Goggins T, Mayer I, Brufsky A, Toppmeyer D, Kaklamani V, Atkins J, Berenberg J, Sledge, George Jr. Prospective Validation of a Multiparameter Assay in Breast Cancer: The New England Journal of Medicine, Manuscript # 15-10764. 2015 Nov. 19; 373; 2005-2014.
 17. Kaufman SA, Harris EE, Bailey L, Chadha M, Dutton SC, Freedman GM, Goyal S, Halyard MY, Horst KC, Novick KL, Park CC, Suh WW, Toppmeyer D, Zook J, Haffty. ACR Appropriateness Criteria® Ductal Carcinoma in Situ. *BG.Oncology (Williston Park).* 2015 Jun;29(6):446-58, 460-1. Review. PMID: 26089220
 18. Rugo HS, Barry WT, Moreno-Aspitia A, Lyss AP, Cirrincione C, Leung E, Mayer EL, Naughton M, Toppmeyer D, Carey LA, Perez EA, Hudis C, Winer EP. Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance). *J Clin Oncol.* 2015;33(21):2361-9. doi: 10.1200/JCO.2014.59.5298. PubMed PMID: 26056183; PMCID: PMC4500830.
 19. Mehta MS, Dolfi SC, Bronfenbrener R, Erhan Bilal E, Chen C, Moore D, Rahim H, Aisner S, Kersellius R, Chen S, Toppmeyer DL, Ganesan S, Vazquez A, Hirshfield KM. GRM1 Expression and its Polymorphic Variants Associate with Breast Cancer Phenotypes. *PLoS ONE*, 8(7): e69851, 2013. doi:10.1371/journal.pone.0069851. (PMCID: PMC3724883).
 20. Bilal E, Vassallo K, Toppmeyer D, Barnard N, Rye IH, Almendro V, Russnes H, Børresen-Dale AL, Levine AJ, Bhanot G, Ganesan S. Amplified Loci on Chromosomes 8 and 17 Predict Early Relapse in ER-Positive Breast Cancers. *PLoS One.* 2012;7(6):e38575. Epub. PMID: 22719901, 2012 June.
 21. Bilal E, Alexe G, Yao M, Cong L., Kulkarni A, Ginja V, Toppmeyer D, Ganesan S, Bhanot G. Identification of the YES1 kinase as a therapeutic target in basal-like breast cancers. *Genes Cancer* 2010; 1(10):1063-73. PMID: 21779430, PMCID: PMC3092264..

22. Vazquez A, Kulkarni D, Grochola LF, Bond GL, Barnard N, Toppmeyer D, Levine AJ, Hirshfield KM. A genetic variant in a PP2A regulatory subunit encoded by the PPP2R2B gene associates with altered breast cancer risk and recurrence. *Int J Cancer*. 2011;128(10):2335-43. doi: 10.1002/ijc.25582. PubMed PMID: 20669227; PMCID: PMC3902652.
23. Mehta MS, Vazquez A, Kulkarni DA, Kerrigan JE, Atwal G, Metsugi S, Toppmeyer DL, Levine AJ, Hirshfield KM. Polymorphic variants in TSC1 and TSC2 and their association with breast cancer phenotypes. *Breast Cancer Res Treat*. 2011;125(3):861-8. doi: 10.1007/s10549-010-1062-1. PubMed PMID: 20658316; PMCID: PMC3876413.
24. Kulkarni D, Vazquez A, Haffty B, Bandera E, Hu W, Sun Y, Toppmeyer D, Levine A, Hirshfield KM. A polymorphic variant in HDMX associates with accelerated age of onset of estrogen receptor negative breast cancer. *Carcinogenesis* (11):1910-5, 2009 November 30.
25. Haffty BG, Choi DH, Goyal S, Silber A, Ranieri K, Matloff E, Lee MH, Nissenblatt M, Toppmeyer D, Moran MS. Breast cancer in young women (YBC): prevalence of BRCA1/2 mutations and risk of secondary malignancies across diverse racial groups. *Ann Oncol*. 2009;20(10):1653-9. doi: 10.1093/annonc/mdp051. PubMed PMID: 19491284.
26. Parikh RR, Housman D, Yang Q, Toppmeyer D, Wilson LD, Haffty BG. Prognostic value of triple-negative phenotype at the time of locally recurrent, conservatively treated breast cancer. *Int J Radiat Oncol Biol Phys*. 2008;72(4):1056-63. doi: 10.1016/j.ijrobp.2008.02.066. PubMed PMID: 18676094
27. Haffty BG, Yang Q, Reiss M, Kearney T, Higgins SA, Weidhaas J, Harris L, Hait W, Toppmeyer D. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. *J Clin Oncol*. 2006;24(36):5652-7. doi: 10.1200/JCO.2006.06.5664. PubMed PMID: 17116942.
28. Bond GL, Hirshfield KM, Kirchhoff T, Alexe G, Bond EE, Robins H, Bartel F, Taubert H, Wuerl P, Hait W, Toppmeyer D, Offit K, Levine AJ. MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. *Cancer Res*. 2006;66(10):5104-10. doi: 10.1158/0008-5472.CAN-06-0180. PubMed PMID: 16707433.
29. Kelly K, Leventhal H, Andrykowski M, Toppmeyer D, Much J, Dermody J, Marvin M, Baran J, Schwalb M. Using the common sense model to understand perceived cancer risk in individuals testing for BRCA1/2 mutations. *Psycho oncology*, 14(1):34-48, 2005 January 2005;14(1):34-48. doi: 10.1002/pon.805. PubMed PMID: 15386791.
30. Kelly K, Leventhal H, Marvin M, Toppmeyer D, Baran J, Schwalb M. Cancer genetics knowledge and beliefs and receipt of results in Ashkenazi Jewish individuals receiving counseling for BRCA1/2 mutations. *Cancer Control*. 2004;11(4):236-44. PubMed PMID: 15284715
31. Kelly K, Leventhal H, Andrykowski M, Toppmeyer D, Much J, Dermody J, Marvin M, Baran J, Schwalb M. The decision to test in women receiving genetic counseling for BRCA1 and BRCA2 mutations. *J Genet Couns*, 13(3):237-57, 2004 June. PubMed PMID: 15604634.
32. Pegram, M, Pienkowski, T, Northfelt D, Eiermann W, Patel R., Fumoleau P, Quan E, Crown J, Toppmeyer D, Smylie M, Riva A, Blita S, Press M, Reese D, Lindsay M and Slamon D. Results of two open label multicenter phase II studies of the synergistic, nonanthracycline based combination of docetaxel, platinum salt, and trastuzumab in HER2- positive advanced breast cancer. *J Natl Cancer Inst.*, 96(10):759-69, 2004 May 19. PubMed PMID: 15150304
33. Kelly K, Leventhal H, Marvin M, Toppmeyer D, Much J, Dermody J, Baran J, Schwalb M. Subjective and objective risk of breast cancer in Ashkenazi Jewish individuals at risk for BRCA1/2 mutations. *Genet Test*. 2004;8(2):139-47. doi: 10.1089/gte.2004.8.139. PubMed PMID: 15345111.
34. Toppmeyer D, Gounder M, Much J, Musanti R, Vyas V, Medina M, Orlando T, Pennick M, Lin Y, Shih W, Goodin S, Rubin E. A phase I and pharmacologic study of the combination of marimastat and paclitaxel in patients with advanced malignancies. *Med Sci Monit*, 9(8):PI99-104, 2003 August. PubMed PMID: 12942041.

35. Licitra EJ, Vyas V, Nelson K, Musanti R, Beers S, Thomas C, Poplin E, Smith S, Lin Y, Schaaf LJ, Aisner J, Gounder M, Rajendra R, Saleem A, Toppmeyer D, Rubin EH. Phase I evaluation of sequential topoisomerase targeting with irinotecan/cisplatin followed by etoposide in patients with advanced malignancy. *Clin Cancer Res.* 2003;9(5):1673-9. PubMed PMID: 12738720.
36. Lindrud S, Orlick M, Hait W, Toppmeyer D. Central nervous system progression during systemic response to trastuzumab, humanized anti-HER2/neu antibody, plus paclitaxel in a woman with refractory metastatic breast cancer. *Breast J.* 9(2):PI5-11, 2003 Mar-Apr. PubMed PMID: 12603385.
37. DiPaola R, Rubin E, Toppmeyer D, Eid J, Butzbach D, Dvorzhinski D, Capanna T, Cairdella M, Shih W, Goodin S, Todd M. Gemcitabine combined with sequential paclitaxel and carboplatin in patients with urothelial cancers and other advanced malignancies. *Med Sci Monit.* 9(2):PI5-11, 2003 February. PubMed PMID: 12601301.
38. Rubin, E. H., de Alwis, D. P., Pouliquen, I., Green, L., Lin, Y., Musanti, R., Grospe, S. L., Smith, S. L., Toppmeyer, D., Much, J., Kane, M., Chaudhary, A., Jordan, C., Burgess, M., Slapak, C. A. A phase I trial of a potent P-glycoprotein inhibitor, zosuquidar (LY335979), administered orally in combination with doxorubicin in patients with advanced malignancy. *Clin Cancer Res.*, 8(12):3710-7, 2002 December. PMID: 12473580
39. Toppmeyer D, Bash-Babula J, Labassi, M, Reidy, J, Orlick M, Alli E, Kearney T, August D Hait W. Induction of p53 and repression of microtubule-associated protein-4 by DNA damage in breast cancer patients: a pilot clinical trial of sequential doxorubicin and vinorelbine. *Clin Cancer Res.* 8(5):1057-64, 2002 May.
40. Toppmeyer D, Seidman AD, Pollak M, Russell C, Tkaczuk K, Verma S, Overmoyer B, Budd GT, Del Prete S, Ferguson S, Stark-Vancs V, Schwartz G, Hainsworth J, Flynn P, Rarick M, Mason B, Ette E, Harding MW, Demetri GD. Safety and efficacy of the MDR inhibitor IncelTM (Biricodar; VX-710) in combination with paclitaxel for advanced breast cancer refractory to paclitaxel. *Clin Cancer Res.*, 8(3):670- 8, 2002 March. PubMed PMID: 11895894.
41. Villalona-Calero MA, Eder JP, Toppmeyer DL, Allen LF, Fram R, Velagapudi R, Myers M, Amato A, Kagen-Hallet K, Razvillas B, Kufe DW, Von Hoff DD, Rowinsky EK. Phase I and pharmacokinetic study of LU79553, a DNA intercalating bisnaphthalimide, in patients with solid malignancies. *J Clin Oncol.* 2001;19(3):857-69. PubMed PMID: 11157040.
42. DiPaola RS, Rafi MM, Vyas V, Toppmeyer D, Rubin E, Patel J, Goodin S, Medina M, Medina P, Zamek R, Zhang C, White E, Gupta E, Hait WN. Phase I clinical and pharmacologic study of 13-cis-retinoic acid, interferon alfa, and paclitaxel in patients with prostate cancer and other advanced malignancies. *J Clin Oncol.* 1999;17(7):2213-8. PubMed PMID: 10561278.
43. Villalona-Calero MA, Baker SD, Hammond L, Aylesworth C, Eckhardt SG, Kraynak M, Fram R, Fischkoff S, Velagapudi R, Toppmeyer D, Razvillas B, Jakimowicz K, Von Hoff DD, Rowinsky E. Phase I and pharmacokinetic study of the water-soluble dolastatin 15 analog LU103793 in patients with advanced solid malignancies. *J Clin Oncol.* 1998;16(8):2770-9. PubMed PMID: 9704730.
44. Eder JP, Rubin E, Stone R, Bryant M, Xu G, Supko J, Kinchla N, Lynch T, Hurwitz S, Rodriguez D, Shapiro C, Toppmeyer D, Grossbard M, Vosburg E, Huberman M, Schnipper L, Shulman L, Kufe DW. Trials of 9-amino-20(S)-camptothecin in Boston. *Ann N Y Acad Sci.* 1996;803:247-55. PubMed PMID: 8993518.
45. Rubin E, Wood V, Bharti A, Trites D, Lynch C, Hurwitz S, Bartel S, Levy S, Rosowsky A, Toppmeyer D, and Kufe D. A phase I and pharmacokinetic study of a new camptothecin derivative, 9-aminocamptothecin. *Clin Cancer Res.*, 1(3):269-76, 1995 March. PubMed PMID: 9815982.
46. Slapak C, Fricasso P, Martell R, Toppmeyer D, Lecerf J, Levy S. Overexpression of the multidrug resistance-associated protein (MRP) genes in vincristine but not doxorubicin-selected multidrug resistant murine erythroleukemia cells. *Cancer Res.* 54(21):5607-13, 1994 November. PubMed PMID: 7923205.

47. Toppmeyer D, Slapak C, Croop J, Kufe, D. Resistance to the cytotoxic peptide dolastatin 10 is conferred by the P-glycoprotein. *Biochem Pharmacol*, 48(3):609-12, 1994 August. 7915113.
48. Rubin E, Pantazis P, Bharti A, Toppmeyer D, Giovanella B, Kufe D. Identification of a mutant human topoisomerase I with intact catalytic activity and resistance to 9-amino-camptothecin. *J Biol Chem.*, 269(4):2433-9, 1994 January. PubMed PMID: 8300570. Lassman C, Matis S, Hall B, Toppmeyer D, Milcarek C. Plasma cell-regulated polyadenylation at the Ig gamma 2b secretion-specific poly(A) site. *J Immunol*, 148(4):1251-60, 1992 February. PubMed PMID: 1346622.

B. Books, Monographs and Chapters

1. Acevedo, P., **Toppmeyer, D.**, and Rubin E. Phase I trial design and methodology for anti-cancer drugs, in Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval. Ed. Beverly Teicher and Paul Andrews. Humana Press: 351-362, 2004.
2. **Toppmeyer DL**, Primary Chemotherapy, in Torosian, M. ed. Breast Cancer-A Guide to Detection and Multidisciplinary Therapy Current Clinical Oncology. Humana Press Inc., 213-226, 2002.
3. Hait, WN, **Toppmeyer, DL** and Dipaola, RS: Medical Treatment of Breast Cancer, in Haffty, B. ed. Expert Consultations in Breast Cancer. Marcel Dekker, Inc., 69-88, 1999.
4. **Toppmeyer, DL** and Garber, JE: Familial Breast Cancer, in Haffty, B. ed. Expert Consultations in Breast Cancer. Marcel Dekker, Inc., 89-95, 1999.
5. Toppmeyer, DL: Phase I Trial Design and Methodology, in Teicher B. ed. Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials and Approval. New Jersey: Humana Press Inc., 227-247, 1997.

C. Patents Held: N/A

D. Other Articles (Reviews, Editorials, etc.) In Journals; Chapters; Books; other Professional Communications

E.

1. Mark Jesus M Magbanua , Laura H Hendrix, Terry Hyslop, William T Barry 3, Eric P Winer, Clifford Hudis, **Deborah Toppmeyer**, Lisa Anne Carey, Ann H Partridge, Jean-Yves Pierga, Tanja Fehm, José Vidal-Martínez, Dimitrios Mavroudis, Jose A Garcia-Saenz, Justin Stebbing, Paola Gazzaniga, Luis Manso, Rita Zamarchi, María Luisa Antelo, Leticia De Mattos-Arruda, Daniele Generali, Carlos Caldas, Elisabetta Munzone, Luc Dirix , Amy L Delson, Harold Burstein, Misbah Qadir, Cynthia Ma, Janet H Scott, François-Clément Bidard, John W Park, Hope S Rugo. "Serial analysis of circulating tumor cells in metastatic breast cancer receiving first-line chemotherapy" *J Natl Cancer Inst* 2020 Aug 8; djaal13. doi: 0.1093/jnci/djaa113. PMID: 32770247
2. Bjorklund S, Panda A, Kumar S, Seiler M, Robinson D, Gheeya J, Ming Y, Alnaes G, **Toppmeyer D**, Riis M, Naume B, Borresen-Dale A, Kristensen V, Ganesan S, Bhanot G. "Widespread alternative exon usage in clinically distinct subtypes of invasive ductal carcinoma" *Scientific Reports*, accepted for publishing; June 2017.
3. Mehrotra S, Sharma MR, Gray E, Wu K, Barry WT, Hudis C, Winer EP, Lyss AP, **Toppmeyer DL**, Moreno-Aspitia A, Lad TE, Valasco M, Overmoyer B, Rugo H, Ratain MJ, Gobburu JV. "Kinetic-Pharmacodynamic Model of Chemotherapy-Induced Peripheral Neuropathy in Patients with Metastatic Breast Cancer Treated with Paclitaxel, Nab-Paclitaxel, or Ixabepilone: CALGB 40502 (Alliance)" *AAPS J*. 2017 Jun 15. doi: 10.1208/s12248-017-0101-9. [Epub ahead of print] PMID: 28620884
4. Morris GJ, Dawood S, Cortes J, Ward JH, Vaklavas C, Forero A, Ward S, **Toppmeyer D**. Sub-centimeter HER2-Positive Breast Cancer: How Small Is Too Small to Treat? *Semin Oncol*. 2015 Aug; 42(4):e67-79. doi: PMID: 26320071 10.1053/j.seminoncol.2015.07.001. Epub 2015 Jul 6. Review. No abstract available.
5. Tian S, Hirshfield KM, Jabbour SK, **Toppmeyer D**, Haffty BG, Khan AJ, Goyal S.

- Serum biomarkers for the detection of cardiac toxicity after chemotherapy and radiation therapy in breast cancer patients. *Front Oncol.* Oct 9;4:277, 2014. doi: 10.3389/fonc.2014.00277. (PMID 25346912; PMCID: PMC4191171)
6. Chojecki A, Wong S, **Toppmeyer D**. Optimal management of the premenopausal patient with estrogen receptor-positive breast cancer. *Am Soc Clin Oncol Educ Book.* 2014:e12-5. doi: 10.14694/EdBook_AM.2014.34.e12. PMID:24857090
 7. Michele Y. Halyard, MD, Eleanor E. R. Harris, MD, Lisa Bailey, MD, Jennifer R. Bellon, MD, Gary M. Freedman, MD, Sharad Goyal, MD, Kathleen C. Horst, MD, Meena S. Moran, MD, Catherine C. Park, MD, W. Warren Suh, MD, **Deborah Toppmeyer, MD**, and Bruce G. Haffty, MD. ACR Appropriateness Criteria® Local-Regional Recurrence (LRR) and Salvage Surgery—Breast Cancer. *CancerNetwork, Oncology Journal, Breast Cancer, Radiation Oncology.* 2014;28(2):157-64, C3. PubMed PMID: 24701707.
 8. Mehta MS, Dolfi SC, Bronfenbrener R, Bilal E, Chen C, Moore D, Lin Y, Rahim H, Aisner S, Kersellius RD, Teh J, Chen S, **Toppmeyer DL**, Medina DJ, Ganesan S, Vazquez A, Hirshfield KM. Metabotropic glutamate receptor 1 expression and its polymorphic variants associate with breast cancer phenotypes. *PLoS One.* 2013 Jul 26;8(7):e69851. doi: 10.1371/journal.pone.0069851. Print 2013. PMID:23922822 [PubMed - indexed for MEDLINE]
 9. Ganesan S, Karantza V, Oza J, **Toppmeyer D**. Triple-negative breast cancers and the human mammary epithelial cell hierarchy. *Breast Dis.,* 32(1-2):49-61. Review.PMID: 22045329, 2010 October.
 10. Wong S, **Toppmeyer D**. Adjuvant chemotherapy for early stage Breast cancer: current trends and future directions. *Current Breast Cancer Reports,* 2:1, 16-24, 2010.
 11. **Toppmeyer DL**, Goodin S. Ixabepilone, a new treatment option for metastatic breast cancer. *Am J Clin Oncol.* 2010;33(5):516-21. doi: 10.1097/COC.0b013e3181b9cd52. PubMed PMID: 20023567.
 12. Tan AR, **Toppmeyer DL**. Ixabepilone in metastatic breast cancer: complement or alternative to taxanes? *Clin Cancer Res.* 2008;14(21):6725-9. doi: 10.1158/1078-0432.CCR-07-4704. PubMed PMID: 18980963.
 13. August, D., **Toppmeyer, D**. Chemoprevention of Breast Cancer, Commentary. *The American Journal of Oncology Review,* 2:325-7, 2003.

F. Abstracts

1. Nadine Tung¹, Banu Arun², Erin Hofstatter,³ Michele R. Hacker¹, **Deborah L Toppmeyer⁴**, Steven J Isakoff⁵, Virginia Borges⁶, Robert D Legare⁷, Claudine Isaacs⁸, Antonio C. Wolff⁹, Paul Kelly Marcom¹⁰, Erica L Mayer¹¹, Paulina B Lange¹¹, Andrew J Goss¹, Ian E Krop¹¹, Eric P Winer¹¹, Stuart J Schnitt¹¹, Judy E Garber¹¹ on behalf of the Translational Breast Cancer Research Consortium. A randomized phase II study of preoperative cisplatin (CDDP) vs doxorubicin/cyclophosphamide (AC) in germline BRCA mutation carriers with newly diagnosed breast cancer (The INFORM trial): TBCRC 031.
2. Chan N, **Toppmeyer DL**. The Final Verdict: Chemotherapy Benefits Estrogen Receptor-Negative Isolated Local Recurrence. *J Clin Oncol.* 2018 Apr 10;36(11):1058-1059. doi: 10.1200/JCO.2017.77.4877. Epub 2018 Feb 27.
3. Mehrotra S¹, Sharma MR, Gray E, Wu K, Barry WT, Hudis C, Winer EP, Lyss AP, **Toppmeyer DL**, Moreno-Aspitia A, Lad TE, Valasco, Overmoyer B, Rugo H, Ratain MJ, Gobburu JV. Kinetic-Pharmacodynamic Model of Chemotherapy-Induced Peripheral Neuropathy in Patients with Metastatic Breast Cancer Treated with Paclitaxel, Nab-Paclitaxel, or Ixabepilone: CALGB 40502 (Alliance). PMID: 28620884: *AAPS J.* 2017 Jun 15. doi: 10.1208/s12248-017-0101-9. [Epub ahead of print]
4. Sharma M, Gray E, Mehrotra S, Wu K, Barry WT, Hudis CA, Winer EP, Lyss AP, **Toppmeyer D**, Moreno-Aspitia A, Rugo HS., Ratain MJ, Gobburu J. A model-based approach to dose optimization of neurotoxic chemotherapy for metastatic breast cancer (MBC). Abstract ID: 151093. ASCO 2015 May.

5. Maria M Zlobinsky Rubinstein, Robert James Gray, Joseph A. Sparano, JoAnne Zujewski, Timothy Joseph Whelan, Kathy S. Albain, Daniel F. Hayes, Charles E. Geyer, Elizabeth Claire Dees, Edith A. Perez, Maccon M. Keane, Carlos Vallejos, Timothy F. Goggins, Ingrid A. Mayer, Adam Brufsky, Deborah Toppmeyer, Virginia G. Kaklamani, James Norman Atkins et al: Recurrence score and clinicopathologic characteristics of TAILORx participants by race and ethnicity, Poster board, 2015 ASCO Annual Meeting, Chicago, IL.
6. Hirshfield KM, Lu S-E, Wong S, Tan A, Kirstein L, Kearney T, Shih W, Ganesan S, **Toppmeyer DL** A Phase II trial of doxil, carboplatin and bevacizumab in metastatic triple negative breast cancer and molecular correlates of response. SABCS 2014.
7. Ganesan S, Alexe G, Hirshfield KM, Yao M, Bhanot G, **Toppmeyer D.** Characterization of the immune infiltrate in HER2+ breast cancer. San Antonio Breast Cancer Symposium 2014. Poster presentation.
8. Antoinette R. Tan, Serena Tsan-Lai Wong, Robert D. Warren, Jennifer Eng-Wong, Minetta C. Liu, Amelia Bruce Zelnak, Yong Lin, Weichung Shih, Shridar Ganesan, Generosa Grana, Claudine Isaacs, **Deborah Toppmeyer**; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ; Lombardi Cancer Ctr, Washington, DC; Genentech, Inc., South San Francisco, CA; Mayo Clinic, Rochester, MN; The Winship Cancer Institute of Emory University, Atlanta, GA; Cooper University Hospital, Camden, NJ; Lombardi Comprehensive Cancer Center, Washington, DC. Phase I/II study of letrozole and sorafenib as first-line therapy of hormone-receptor positive (HR+) metastatic breast cancer (MBC). Poster presentation. 2014 ASCO Annual meeting; Chicago, IL
9. Joseph A. Sparano, Robert J Gray, Jo Anne Zujewski, Timothy Joseph Whelan, Kathy S. Albain, Daniel Hayes, Charles E Geyer, Elizabeth Claire Dees, Edith A. Perez, Maccon M. Keane, Carlos Vallejos Sologuren, Timothy F Goggins, Ingrid A. Mayer, Adam Brufsky, **Deborah L Toppmeyer**, Virginia G Kaklamani, James N Atkins, Jeffrey L Berenberg, George W. Sledge; Montefiore Medical Center, Bronx, NY; Dana-Farber Cancer Institute, Boston, MA; National Cancer Institute at the National Institutes of Health, Bethesda, MD; Juravinski Cancer Centre, Hamilton, ON, Canada; Loyola University Medical Center, Maywood, IL; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Allegheny Cancer Center, Pittsburgh, PA; UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC; Mayo Clinic, Jacksonville, FL; Department of Medical Oncology, University College Hospital Galway, Galway, Ireland; Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru; Fox Valley Hematology and Oncology, Appleton, WI; Vanderbilt-Ingram Cancer Center, Nashville, TN; University of Pittsburgh Medical Center, Pittsburgh, PA; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ; Northwestern University, Chicago, IL; S.E. Cancer Control Consortium, Goldsboro, NC; University of Hawaii MBCOPP, Honolulu, HI; Stanford University, Palo Alto, CA, Recurrence score and clinicopathologic characteristics of TAILORx participants by race and ethnicity. 2014 Breast Cancer Symposium
10. Antoinette R. Tan, **Deborah Toppmeyer**, Serena Tsan-Lai Wong, Hongxia Lin, Murugesan Gounder, Rebecca Anne Moss, Mark N. Stein, Janice M. Mehnert, Sinae Kim, Alice P. Chen, Robert S. DiPaola; The Cancer Institute of New Jersey, New Brunswick, NJ; National Cancer Institute, Bethesda, MD: Assessment of γ H2AX levels in circulating tumor cells in patients treated with veliparib in combination with doxorubicin and cyclophosphamide in metastatic breast cancer. General Poster Session, Developmental Therapeutics - Clinical Pharmacology and Experimental Therapeutics 2013 ASCO Annual Meeting
11. Pashna Neville Munshi, **Deborah Toppmeyer**, Serena Tsan-Lai Wong, Shridar Ganesan, Katherine Hanna Tkaczuk, Mary E. Cianfrocca, Virginia G. Kaklamani, William John Gradishar, Robert A. Somer, Kanu Sharan, Generosa Grana, Pauline Marie O. Lerma, Lillian F. Pliner, Robert Wieder, Michael P. Kane, Sinae Kim, Antoinette R. Tan; University of Medicine and Dentistry of New Jersey-Robert Wood Johnson University Hospital, New Brunswick, NJ; The Cancer Institute of New Jersey, New Brunswick, NJ; University of Maryland, Marlene and Stewart

- Greenebaum Cancer Center, Baltimore, MD; Banner MD Anderson Cancer Center, Gilbert, AZ; Northwestern University, Chicago, IL; Cooper University Hospital, Camden, NJ; UMDNJ-New Jersey Medical School, Newark, NJ. Randomized phase II trial of gemcitabine versus gemcitabine and imatinib mesylate in patients with previously treated metastatic breast cancer. Poster presentation: 2013 ASCO Annual Meeting; Chicago, IL
12. Rugo HS, Barry WT, Moreno-Aspitia A, Lyss A, Cirrincione C, **Toppmeyer D**, Mayer E, Naughton M, Layman RM, Carey LA, Somer RA, Perez EA, Hudis C, Winer E. CALGB 40502/NCCTG NO63H: Randomized Phase III Trial of Weekly Paclitaxel (P) Compared to Weekly Nanoparticle Albumin Bound Nab-Paclitaxel or Ixabepilone +/- Bevacizumab as First-Line Therapy for locally recurrent or metastatic Breast Cancer. 2012 ASCO Annual Meeting Oral Abstract Session, Breast Cancer – Triple-Negative/Cytotoxics/Local Therapy. Citation: J Clin Oncol 30, 2012 (suppl; abstr CRA1002)
 13. Mehta MS, Dolfi SC, Bronfenbrener R, Bilal E, Medina D, Haffty B, **Toppmeyer D**, Ganesan S, Hirshfield KM. Role of GRM1 in Breast Cancer.. Presented (poster presentation) at the AACR Annual Meeting 2012, Chicago, I.L.
 14. Dolfi SC, Kulkarni D, Lu S, Chen C, Moore D, Vazquez A, Harris S, Toppmeyer D, Levine AJ, Hirshfield KM. Prognostic Role of Perp in Breast Cancer. Presented (poster presentation) at the AACR Annual Meeting 2012, Chicago, I.L.
 15. A. R. Tan, **D. Toppmeyer**, M. N. Stein, R. A. Moss, M. Gounder, D. C. Lindquist, J. J. Ji, A. P. Chen, M. J. Egorin, B. Kiesel, J. H. Beumer, R. S. DiPaola; Cancer Institute of New Jersey, New Brunswick, NJ; The Cancer Institute of New Jersey, New Brunswick, NJ; SAIC-Frederick, Bethesda, MD; National Cancer Institute, Bethesda, MD; University of Pittsburgh Cancer Institute, Pittsburgh, PA. Phase I trial of veliparib, (ABT-888), a poly(ADP-ribose) polymerase (PARP) inhibitor, in combination with doxorubicin and cyclophosphamide in breast cancer and other solid tumors; J Clin Oncol 29: 2011 (suppl; abstr 3041), 2011 ASCO Annual Meeting, Chicago, IL
 16. J.K. Campbell, L. Liang, H. Vig and **Toppmeyer, D**. "BioCONNECT (Biology and Cancer, Online Education Connecting Teens): An innovative and interactive high school curriculum" presented at the National Science Teachers Association Annual Meeting, San Francisco, CA, 2011 March.
 17. Tan, AR, Reiss M, Wong S, Huzzy L, Tierney C, Surman M, **Toppmeyer D**. Letrozole and sorafenib as first-line therapy in postmenopausal women with hormone-receptor positive (HR+) metastatic breast cancer (MBC): preliminary results. ASCO, Chicago, 2011.
 18. J.K. Campbell, L. Hemminger, H. Vig and **Toppmeyer, D**. "BioCONNECT (Biology and Cancer, Online Education Connecting Teens): An innovative and interactive high school curriculum" presented at the South Carolina Science Council Annual Meeting, Myrtle Beach, SC, 2010 November.
 19. J.K. Campbell, L. Hemminger, H. Vig and **Toppmeyer, D**. "BioCONNECT (Biology and Cancer, Online Education Connecting Teens): An innovative and interactive high school curriculum" presented at the Annual New Jersey Science Convention, Somerset, NJ, 2010 October.
 20. Basavanhally A, Xu J, **Toppmeyer D**, Barnard N, Bhanot G, Madhabhushi A, and Ganesan S. Computer-Aided Image-Analysis based Classification of ER+ Breast Cancer Histology. San Antonio Breast Cancer Symposium, San Antonio, TX 2009.
 21. Aly A, Bouwman P, Yang Q, Yao M, Bilal E, Bhanot G, Haffty B, **Toppmeyer D**, Jonkers J and Ganesan S, 53BP1 Abnormalities in human basal-like breast cancer. San Antonio Breast Cancer Symposium, San Antonio, TX, 2009.
 22. Kulkarni DA, Vazquez A, Haffty BG, Bandera EV, Hu W, Sun YY, **Toppmeyer DL**, Levine AJ, Hirshfield KM. A polymorphic variant in human MDM4 associates with accelerated age of onset of estrogen receptor negative breast cancer. Carcinogenesis. 2009;30(11):1910-5. doi: 10.1093/carcin/bgp224. PubMed PMID: 19762336; PMCID: PMC3895963.
 23. Rahim H, Kulkarni D, **Toppmeyer D**, Hirshfield KM. Effect of Reproductive

- Characteristics and BMI on Age of Diagnosis in Breast Cancer. Annual Retreat on Cancer Research, Piscataway, NJ. 2009
24. Jäger A, Hait WN, **Toppmeyer D**, Haffty B, Hirshfield K, Yang JM. Fulvestrant Decreases MDM2 Expression and Enhances Sensitivity of Human Breast Carcinoma Cells to Chemotherapeutic Drugs. Annual Retreat on Cancer Research. Piscataway, NJ. 2009
 25. Jager A., Hirshfield K., Hait WN, **Toppmeyer D**, B. Haffty, JM Yang. The selective estrogen receptor down-regulator, fulvestrant, decreases MDM2 expression and enhances sensitivity of human breast carcinoma cells to chemotherapeutic drugs. AACR 100th Annual Meeting, 2009, Abstracts p. 280.
 26. Patrick-Miller L, Cummings S, Fetzer D, Schmidheiser H, Daly MB, **Toppmeyer D**, Olopade O, Bradbury AR. Telephone disclosure of BRCA1/2 test results. Experience and opinions of consumers and genetic counselors. 11th International Meeting on the Psychosocial Aspects of Genetic Testing for Hereditary Cancer, Philadelphia, PA. 2009 November.
 27. Hemminger L, Campbell J, Vig H, Toppmeyer D. BioCONNECT (Biology and Cancer, Online Education Connecting Teens): An innovative and interactive high school curriculum. APHA annual meeting oral presentation, Philadelphia, PA., 2009 November.
 28. Patrick-Miller L, Cummings S, Fetzer D, Schmidheiser H, Daly MB, **Toppmeyer D**, Olopade O, Bradbury AR. The disclosure of BRCA1/2 test results: Opinions of recipients of BRCA1/2 testing. Breast Cancer Research and Treatment, San Antonio Breast Cancer Symposium, San Antonio, TX, 2008 December, 2098.
 29. Hirshfield KM, Bond GL, Bond EE, Harris S, **Toppmeyer DL**, Levine AJ. Mdm2 SNP309 Accelerates Tumor Formation in a Hormonal Dependent Manner and Affects the Function of P53 in Cancer. Presented (oral presentation) at the 13th Annual P53 Workshop 2007, Columbia University, N.Y.
 30. Haffty B, Choi DH, Moran MS, Silber A, Matloff E, Lee MH, Ranieri K, **Toppmeyer D**. Racial differences in frequency and spectrum of BRCA1/2 mutations in young women with breast cancer. Breast Cancer Research and Treatment, San Antonio Breast Cancer Symposium, San Antonio, TX 2007 December, 3045
 31. Haffty B, Yang, Q, Reiss M, Kearney W. Hait W. **Toppmeyer D**. Local-regional relapse and distant metastasis in conservatively managed triple negative early stage breast cancer. Proceedings of American Society of Clinical Oncology, 2006, 24:594.
 32. **Toppmeyer D**, Nyak M, Chang J-M, Huzzy L, Shah N, Hait WN. The role of mediated alteration of microtubule dynamics to sensitize breast cancer to vinca alkaloids. Breast Cancer Research and Treatment, 2005, Vol.94 Supplement 1:1078 p53.
 33. Kelly, K, Leventhal, H, **Toppmeyer, D**, Baran,J, Schwalb, B. Women at increased risk for ovarian cancer: Attitudes about ovarian cancer screening. Annals of Behavioral Medicine, 2003 March, 25, Supplement.
 34. **Toppmeyer D**, Kaufman, P, Crump, M, Sessa C, Mapkey J, Stein S, Anderson J, Shortall J, Rothermel J. Preliminary results from an open-label phase IIa trial evaluating the safety and efficacy of EPO906 in patients with advanced breast cancer. Breast Cancer Research and Treatment, San Antonio Breast Cancer Symposium, San Antonio, TX, 2002 December, Vol 76, Supplement 1:534.
 35. Patrick-Miller L, Kelly K, **Toppmeyer D**, Leventhal H, Much J, Baron J, Schwalb M. Breast Cancer Screening Behaviors and Perceived Control in Individuals Interested in Testing for BRCA1/2 Mutation. Proceedings of American Society of Clinical Oncology; ASCO 2001, 20: 1911.
 36. Kearney T, Rafi M, Reidy J, Orlick M, Labassi M, Hait W, **Toppmeyer D**, DiPaola R. 13-cis-Retinoic Acid, Alpha-Interferon and Paclitaxel: Activity and Effect on bcl-2 Expression in Patients with Advanced Breast Carcinoma. Proceedings of American Society of Clinical Oncology; ASCO 2001, 20:195.
 37. Slamon D, Patel R, Northfelt R, Pegram M, Rubin J, Sebastian G, Tannenbaum S, Sanchez J, Quan E, **Toppmeyer D**, Overmoyer B, Nabholtz J. Phase II pilot study

- of herceptin combined with taxotere and carboplatin (TCH) in metastatic breast cancer (MBC) patients overexpressing the HER2/neu proto-oncogene. Proceedings of American Society of Clinical Oncology; ASCO 2001, 20:193.
38. **Toppmeyer D**, Bash-Babula J, Alli E, Kearney T, Smirnov E, Reidy J, Orlick M, Labassi M, Hait W. Sensitization of Breast Cancer Patients to Vinorelbine (V) Following p53 Induction and MAP4 Repression by Doxorubicin (DOX): A Phase I/II Study. Proceedings of American Society of Clinical Oncology; ASCO 2001, 20: 182.
 39. Bash-Babula J, Toppmeyer D, Labassi M, Reidy J, Orlick M, Senzon R, Alli E, Kearney T, August D, Shih W, Yang JM, Hait WN. A Phase I/pilot study of sequential doxorubicin/vinorelbine: effects on p53 and microtubule-associated protein 4. Clin Cancer Res. 2002;8(5):1057-64. PubMed PMID: 12006519.
 40. **Toppmeyer D**, Bash-Babula J, Alli E, Kearney T, Reidy J, Labassi M, Hait W. Sensitization of breast cancer patients to vinorelbine (V) following p53 induction and MAP4 repression by doxorubicin (DOX). Proceedings of American Society of Clinical Oncology; ASCO 2001.
 41. Baran J, Kelly K, Leventhal H, Schwalb M, **Toppmeyer D**, Much J, Magee M. Quality of life in individuals testing for BRCA1 and BRCA2 mutations. Proceedings from the American Society of Clinical Oncology; ASCO 2000, 19: 2423.
 42. Zamek R.M, **Toppmeyer D**, Vyas V, Saleem A, Much J, Poplin E, Medina M, Lin Y, Schaaf J, Rubin E. A phase I and pharmacologic evaluation of sequential topoisomerase (Top) targeting with irinotecan (I) and etoposide (E) in combination with cisplatin (P). Proceedings from the American Society of Clinical Oncology; ASCO 2000, 19: 773.
 43. **Toppmeyer D**, Rafi M, Cohen S, Ocasio F, Goodin S, Aisner J, Hait W, DiPaola RS. Clinical and biological activity of 13-cis-retinoic acid, alpha-interferon, and paclitaxel in patients with advanced breast carcinoma. Proceedings from the American Society of Clinical Oncology; ASCO 2000, 19: 591.
 44. Rafi M, Kotenko S, Pestka S, **Toppmeyer D**, Hait W, and Dipaola RS: Cytotoxicity and bcl-2 modulation by interferon alpha. Proceedings of American Cancer Research; ASCO 1999, 40:3179.
 45. Todd M, Rubin E., Medina, M, Zamek R, Much J., Wojtaszek C. Kane M, Poplin E., Eid J, Hait W, Toppmeyer D. Gemcitabine, carboplatin, and paclitaxel: an active, tolerable treatment for advanced malignancy. Proceedings of American Society of Clinical Oncology; ASCO 1999:887.
 46. Rubin E, Zamek R, Medina M, Much J, **Toppmeyer D**, Luffer-Atlas A, Chaudhary A., Green L, Marder P, Jordan D. Skerjanec A, Slapak C. A Phase I Trial of LY335979, a potent multidrug-resistance modulator administered orally in combination with doxorubicin. Proceedings of American Society of Clinical Oncology; ASCO 1999, 705.
 47. **Toppmeyer D**, Overmoyer B, Seidman A, Del Prete S, Pollack M, Verma S, Ferguson S, Schwartz G, Tkaczuk K, Stark-Vancs V, Mason B, Flynn P, Russell C, Weisberg T, Hainsworth J, Purdy S, Moseley S, Ette E, Harding M, Demetri G. A phase II study of VX-710 (Incel™) in combination with paclitaxel in women with advanced breast cancer refractory to paclitaxel. Breast Cancer Research and Treatment. 21st Annual San Antonio Breast Cancer Symposium, 1998 December, Vol 50, No.3:520..
 48. Villalona-Calero M, Eder P. **Toppmeyer D.**, Allen L, Velagapudi R, Myers M, Amato A, Kagen-Hallet K, Razvillas B, O'Conner L, Fram R, Kufe D, Von Hoff D, Rowinsky E. Phase I and pharmacokinetic (PK) study of LU79553, a novel bis-naphthalamide on a daily x 5 schedule. Proceedings of American Society of Clinical Oncology; ASCO 1998.
 49. **Toppmeyer D**, Lynch T, Grossbard M, Bryant M, Kinchla N, Eder F, Kufe D, Stone R. A phase I clinical and pharmacodynamic study of all-trans retinoic acid and bryostatins in patients with advanced malignancies. Proceedings from the American Society of Clinical Oncology; ASCO 1996; 15 482.

G. Reports: N/A

PRESENTATIONS:

A. Scientific: N/A

B. Professional:

1. Invited as expert, CME program - Oncology Round Table, Virtual Summit. ASCO Update: Breast Cancer. June 27, 2020
2. Invited Speaker, Staying Up to Date on the Treatment of Advanced HR-Positive, HER2-Negative Breast Cancer, AXIS Medical Education, Alexandria, VA. May 24, 2017.
3. Invited Speaker, AXIS Medical Education, Staying Up to Date on the Treatment of Advanced HR-Positive, HER2-Negative Breast Cancer, West Palm Beach, FL. March 8, 2017.
4. Invited Speaker, Updates from SABCS on Metastatic Breast Cancer, Cancer Care teleconference, February 9, 2017.
5. Invited Speaker, Novel approaches for HR+/HER2-Advanced Breast Cancer: Making Informed clinical Decisions for Your Patients, AXIS Medical Education, Alexandria, VA: November 30, 2016
6. Invited Speaker, IMEDEX-Grand Rounds: “Emerging Treatment Strategies of Advanced and Metastatic ER+ Breast Cancer: The Clinical Potential of CDK4/6 Inhibitors” Citizens Medical Center, Victoria, TX: July 27, 2016
7. Invited Speaker, AXIS Medical Education: “Novel Approaches for HR+/HER2-Neg Advanced Breast Cancer: Making Informed clinical Decisions for your Patients”: MedStar Washington Hospital Center, Washington, DC: July 8, 2016
8. Invited Speaker, CME Grand Rounds, “Emerging Treatment Strategies for Advanced and Metastatic ER+ Breast Cancer”: The Clinical Potential of CDK 4/6 Inhibitors, Thomas Jefferson University Memorial Hospital – Philadelphia, PA: January 13 2016.
9. Invited Speaker, Lynn Sage Breast Cancer Symposium, Connie Moskow Memorial Debate, “Extended Adjuvant Endocrine Therapy Is Optimal for All (ER+) Patients (Debate)”, Chicago IL, October 28 – 31, 2015.
10. Invited Speaker, Novel approaches for HR+/HER2-Advanced Breast Cancer: Making Informed clinical Decisions for Your Patients, AXIS Medical Education, Shreveport, LA: October 2, 2015
11. Invited Speaker, ACP New Jersey Chapter Scientific Meeting 2015, “Advances in Cancer Treatment for General Internists: Breast and Colon Cancer,” Iselin, NJ, March 6, 2015.
12. Invited Speaker, ASCO Speaker Session: Navigating a Changing Sea: Optimizing Treatment of Hormone Receptor-Positive Breast Cancer; Title of Speech: “Ovarian Suppression in Premenopausal Patients: Why, How, When”, 2014 ASCO Annual meeting, Chicago, IL, May 30- June 3, 2014.
13. Co-Chair in the Oral Abstract Session, as well as, a Discussant in the Highlights of the Day III Session. 2013 ASCO Annual meeting, Chicago, IL, June 1-4, 2013.
14. Invited Speaker, Morristown Memorial Hospital, San Antonio Breast Cancer Symposium 2012 Review, “Hormonal Therapy of Breast Cancer”, Morristown, NJ, February 2, 2013.
15. Invited Speaker, “Medlearning Inc., Emerging Therapeutic Strategies in Heavily Pretreated Metastatic Breast Cancer”, Atlanta, GA, September 24, 2012.
16. Invited Speaker, 18th Annual Perspectives in Breast Cancer, “HER2+ Breast Cancer in Metastatic Setting” and “Do all HER2+ ER+ Breast Cancers Require Chemotherapy?” New York, NY, August 18, 2012.
17. Invited Speaker, 2012 Oncology Highlights: News from the Annual Oncology Meeting, topics on “Breast Cancer”, New York, NY, July 14, 2012

18. Invited Speaker, Session: 2012 Oncology Highlights: News From The Annual Meeting of The American Society Of Clinical Oncology Presentation:” Breast Cancer,” New York, NY, July 8, 2012.
19. Invited Speaker, San Antonio Breast Cancer Symposium 2011 Review, “Hormonal Therapy of Breast Cancer”, Morristown, NJ, February 8, 2012.
20. Invited Speaker, “Maximizing Benefits; Minimizing Risks in Metastatic Breast Cancer”, Blumenthal Cancer Center, Paramus, NJ, May 21, 2012.
21. Invited Speaker, Medlearning Inc., “Emerging Therapeutic Strategies in Heavily Pretreated Metastatic Breast Cancer”, Berkshire Medical Center, Pittsfield, MA, December 21, 2011.
22. Invited Speaker, “Maximizing Benefits; Minimizing Risks in Metastatic Breast Cancer “, St. Mary’s Hospital, Richmond, VA, November 2011.
23. Invited Speaker, MedLearning Inc., “Emerging Therapeutic Strategies in Heavily Pretreated Metastatic Breast Cancer”, City of Hope, Duarte, CA, September 20, 2011.
24. Invited Speaker, Living Beyond Breast Cancer Networking Meeting, “Metastatic Breast Cancer: Understanding Your Treatment Options”, Cherry Hill, NJ, June 8, 2011.
25. Invited Speaker, Cooper Health System, “Advances, Breakthroughs, and Controversies in Breast Cancer Treatment Trials and the Future of Currently Used Agent”, Voorhees, NJ, May 27, 2011.
26. Invited Speaker, 4th Annual Jean Sindab Triple-Negative Breast Cancer Symposium, “Management of High Risk Patients”, Atlanta, GA, May 13, 2011.
27. Chair/Speaker, Community Oncology Information Network (COIN), Los Angeles, CA, March 27, 2011.
28. Invited Speaker, Post San Antonio “Hormone Treatment”, “Hormone Therapy & Obesity in Breast Cancer”, Roslyn, NY, March 10, 2011.
29. Invited Speaker, St. Edward Mercy Medical Center, “The Changing Paradigm in Breast Cancer Treatment”, Ft. Smith, Arkansas, February 24, 2011.
30. Invited Speaker, Morristown Memorial Hospital, San Antonio Breast Cancer Symposium 2010 Review, “Hormonal Therapy of Breast Cancer”, Morristown, NJ, January 29, 2011.
31. Invited Speaker, Brooklyn Hospital Center, “The Changing Paradigm in Breast Cancer Treatment”, Brooklyn, NY, January 13, 2011.
32. Invited Speaker, IMEDEX, Educational Series, “Protecting Bone Health in Patients: A Focus on Breast and Prostate Cancer: The Future of Bone Care in Cancer Patients”, New York, NY, December 14, 2010.
33. Invited Speaker, Breast Conference – CINJ Network Program, Morristown, NJ, November 18, 2010.
34. Invited Speaker, Living Beyond Breast Cancer’s Annual Fall Conference, “Triple-Negative Breast Cancer: Medical and Lifestyle Update”, Philadelphia, PA, November 13, 2010.
35. Invited Speaker, Lynn Sage Breast Cancer Symposium, “Treatment of T1a T1b HER2 positive breast cancer”, Chicago, IL, October 31, 2010.
36. Invited Speaker, The Wellness Community of Central NJ, “Advanced Breast Cancer”, Bedminster, NJ, October 20, 2010.
37. Invited Speaker, BJ’s Pink Picnic, Edison, NJ, October 6, 2010.
38. Invited Speaker/Consultant, Expert Advisors in Cancer Therapy (EXACT), Bristol-Myers Squibb, St. Louis, MI, June 18, 2010.
39. Invited Speaker, Great Debates and Updates in Breast Cancer, “Didactic: Is Gene Expression Profiling Useful in Treatment Planning for Node Positive Breast Cancer?” San Francisco, CA, May 7, 2010.
40. Invited Speaker, “State of the Art Breast Cancer Care: The Next Decade of Novel Therapies”, East Orange General Hospital, East Orange, NJ, April 27, 2010.
41. Invited Speaker, “State of the Art Breast Cancer Care: The Next Decade of Novel Therapies”, Flushing Hospital Medical Center, Flushing, NY, April 20, 2010.

42. Invited Speaker, Roche Lectureship, “New Frontiers in Managing Metastatic Breast Cancer”, Cancer Institute of NJ, New Brunswick, NJ, October 20, 2009.
43. Invited Speaker, Educational Symposium, Critical Choices for the Cancer patient: Updates, Advances and New Options, “Putting the Pieces Together: Breast Cancer Management in 2009”, Los Angeles, CA, October 17, 2009.
44. Invited Speaker, Community Medical Center Medical Staff, “Putting the Pieces Together: Breast Cancer Management in 2009”, Toms River, NJ, September 24, 2009.
45. Invited Speaker, Novartis Program, “Adjuvant Therapy for Early Breast Cancer”, Newton, PA, September 23, 2009.
46. Invited Speaker, American Cancer Society-Making Strides Against Breast Cancer, Iselin, NJ, August 13, 2009.
47. Invited Speaker, Mayo Clinic 19th Annual Hematology/Oncology Review, “Uterine Cancer and Genetic Susceptibility”, Amelia Island, FL, July 30- August 1, 2009.
48. Invited Speaker, Novartis Program, “Adjuvant Therapy for Early Breast Cancer”, Red Bank, NJ, July 22, 2009.
49. Invited Speaker, “ASCO Update 2009, Breast Cancer”, Morristown Memorial Hospital, Morristown, NJ, June 20, 2009.
50. Invited Speaker, Ninth Annual New Strategies in Breast Cancer Conference, “Future Targets in Metastatic Breast Cancer”, Philadelphia, PA, April 2-4, 2009.
51. Invited Speaker, Novartis Program, “Adjuvant Therapy for Early Breast Cancer”, Steeplechase Cancer Center, Somerville, NJ, March 25, 2009.
52. Invited Speaker, 15th Annual NOCR Meeting, “Meet the Expert: Advances in the Management of ER/PR+ Breast Cancer”, Las Vegas, Nevada, March 13-14, 2009.
53. Invited Speaker, San Antonio Update 2008, “Hormonal Therapy and Bone Health”, Morristown Memorial Hospital, Morristown, NJ, January 24, 2009.
54. Moderator, “Treatment-refractory Metastatic Breast Cancer: New Options and Emerging Strategies”. CME Arc Mesa Educators, November 10, 2008.
55. Invited Speaker, New Jersey Cancer Survivorship Conference, “Medical Management Issues in Cancer Survivorship”, Mount Laurel, NJ, November 5, 2008.
56. Invited Speaker, “Management and Treatment of BRCA1/2 Mutation Carriers: Progress?” Morristown Memorial Hospital, Morristown, NJ, October 28, 2008.
57. Invited Speaker, Lunch and Learn on behalf of the Val Skinner Foundation, NY, NY, October 22, 2008.
58. Invited Speaker, “Improving Patient Outcomes: Maximizing New and Existing Treatment Options”, Oncology Registrar Association of NJ Annual Meeting, Atlantic City, October 16, 2008.
59. Invited Speaker, Tied to the Cure Breast Cancer Conference, RWJUH, New Brunswick, NJ October 10, 2008.
60. Invited Speaker, “Updates in the Neoadjuvant Treatment of Breast Cancer”, Easton Hospital, Easton PA, October 7, 2008.
61. Invited Speaker, “Controversies in Premenopausal Endocrine Treatment”, Current Controversies and New Horizons, Harvard Medical School, Boston, MA, July 12, 2008.
62. Invited Participant, Post-ASCO Live Faculty Training, Educational Concepts Group, Inc., Las Vegas, Nevada, June 19 – 20, 2008 .
63. Invited Faculty, American Society of Clinical Oncology, Education Session, “Uterine Cancer and the Lynch Syndrome”. Chicago, IL, May 30-June 2, 2008.
64. Invited Speaker, “CME Update on Breast Cancer”, Educational Concepts, Fountain Valley Regional Hospital, Fountain Valley, CA, April 18, 2008.
65. Invited Speaker, “An Update in the Treatment of HER2-Positive Metastatic Breast Cancer”, Saint Joseph’s Hospital, Paterson, NJ, February 20, 2008.
66. Invited Speaker, “Hormonal Treatments in Metastatic Disease”, Post San Antonio Update, Morristown Memorial Hospital, Morristown, NJ, February 9, 2008.
67. Invited Speaker, “What is Triple Negative Breast Cancer, Triple Negative Breast Cancer Foundation – Saks Fifth Avenue Fundraiser, The Shops at Riverside Mall, Hackensack, NJ, February 6, 2008.

68. Invited Speaker, "Genetics and Breast Cancer", Medical Grand Rounds, University Medical Center At Princeton, Princeton, NJ, November 20, 2007.
69. Invited Speaker, "Switch Therapy: A new Approach to Adjuvant Hormonal Therapy", Robert Wood Johnson University Hospital, New Brunswick, NJ, October 17, 2007.
70. Invited Speaker, "The Latest in Treatment for Breast Cancer", Tied to the Cause: Recent Advances in Breast Cancer Diagnosis and Treatment, Robert Wood Johnson University Hospital, New Brunswick, NJ, October 16, 2007.
71. Invited Speaker, "Development and Integration of Treatment Strategies in Breast Cancer", North Shore-Long Island Jewish Health System, Forest Hills Hospital, Forest Hills, NY, October 3, 2007.
72. Invited Speaker, "Expanding Chemotherapy Options for Patients with Advanced Breast Cancer", Lynn Sage Breast Cancer Symposium, Robert L. Lurie Comprehensive Cancer Center, Northwestern University, The Fairmont Chicago, Chicago, IL, September 27-30, 2007.
73. Invited Speaker, Grand Rounds, "Breast Cancer – Risk Factors", Raritan Bay Medical Center, Perth Amboy, NJ, September 11, 2007.
74. Invited Speaker, "Inside Breast Cancer: Current and Emerging Treatment Options", Mt Nittany Medical Center, State College, PA, August 1, 2007.
75. Invited Speaker, "Switch Therapy: A new Approach to Adjuvant Hormonal Therapy", Pfizer Oncology, Staten Island University Hospital, Staten Island, NY, July 27, 2007.
76. Invited Speaker, "A Review of the Latest Data in Metastatic Breast Cancer", Bayonne Medical Center, Bayonne, NJ, July 25, 2007.
77. Invited Participant, Herceptin Speakers' Bureau Development Meeting, Genentech Integrated Education, Le Parker Meridien Hotel, NY, NY, July 13, 2007.
78. Invited Speaker, "ASCO Update 2007", Post ASCO Solid Tumor Review, North Shore University Hospital, Great Neck, NY, June 27, 2007.
79. Invited Speaker, "ASCO Update 2007", ASCO 2007 Review, Morristown Memorial Hospital, Morristown, NJ, June 23, 2007.
80. Invited Speaker, "Management of Chemotherapy-Related Complications: A Case-Based Approach to the Management of Chemotherapy Related Bone Loss", Philadelphia, PA, April 25, 2007.
81. Invited Speaker, "Optimizing Adjuvant Hormonal Therapy for Postmenopausal Women With Early Stage Breast Cancer", Grand Rounds, St. Clare's Hospital, Schenectady, NY, March 13, 2007.
82. Invited Speaker, "Optimizing adjuvant Hormonal Therapy for Postmenopausal Women with Early Stage Breast Cancer", Columbus Hospital, Newark, NJ March 12, 2007.
83. Invited Speaker, "Optimizing Adjuvant Hormonal Therapy for Postmenopausal Women With Early Stage Breast Cancer", Grand Rounds, Jamaica Hospital Medical Center, Jamaica, NJ, March 7, 2007.
84. Invited Speaker, "Understanding Early Breast Cancer: A Review of Als in the Adjuvant Setting", University of Miami Sylvester Cancer Center, Miami, FL, February 7, 2007.
85. Invited Speaker, "Optimizing Adjuvant Hormonal Therapy for Postmenopausal Women With Early Stage Breast Cancer", Grand Rounds, St. Mary's Hospital, Passaic, NJ, January 31, 2007.
86. Invited Speaker, "Inside Breast Cancer: Current and Emerging Treatment Options", St. Luke's Roosevelt Hospital, New York, NY, January 17, 2007.
87. Invited Speaker, "Optimizing Adjuvant Hormonal Therapy in Postmenopausal Women With Early Stage Breast Cancer", Fawcett Memorial Hospital, Port Charlotte, FL, November 4, 2006.
88. Invited Speaker, "Inside Breast Cancer: Current and Emerging Treatment Options", Bayonne Medical Center, Bayonne, NJ, October 11, 2006.

89. Invited Speaker, Grand Rounds, "Optimizing Adjacent Hormonal Therapy for Post Menopausal Women with Breast Cancer", Jersey City Medical Center, Jersey City, NJ, October 4, 2006.
90. Invited Speaker, "Breast Cancer", ASCO 2006 Review, Carol G. Simon Cancer Center at Morristown Memorial Hospital, Morristown, NJ, July 15, 2006.
91. Invited Speaker, "BRCA 1&2: Implication in Breast Cancer", Medical Grand Rounds, Raritan Bay Medical Center, Perth Amboy, NJ, April 18, 2006.
92. Invited Speaker, Inside Breast Cancer: "The Evolution of Hormone Therapy", Zalmin Arlin Cancer Center, Valhalla, NY, February 16, 2006.
93. Invited Speaker, "Endocrine Therapy: Highlights from the San Antonio Breast Cancer Symposium", NOCR Update, Chicago, IL, February 4, 2006.
94. Invited Speaker, "Applying Practice to Science: Highlights from the 2005 San Antonio Breast Cancer Symposium", Morristown Memorial Hospital, Morristown, NJ, January 28, 2006.
95. Invited Speaker, "Applying Practice to Science: Highlights from the 2005 San Antonio Breast Cancer Symposium, Atlanta, GA, January 14, 2006.
96. Invited Speaker, "Identifying and Managing Hereditary Breast/Ovarian Cancer", Robert Wood Johnson University Hospital at Hamilton, NJ, October 27, 2005.
97. Invited Speaker, "The Evolution of Hormone Therapy", Saint Vincent Catholic Medical Centers, Jamaica, NY, October 20, 2005.
98. Invited Speaker, "The Evolution of Hormone Therapy", Hartford, Connecticut, October 11, 2005.
99. Invited Speaker, "Adjuvant Endocrine Therapy of Breast Cancer "Clinical Applications: Highlights from the 2004 San Antonio Breast Cancer Symposium", Buffalo, NY, March 16, 2005.
100. Invited Speaker, "Adjuvant Endocrine Therapy of Breast Cancer Clinical Applications: Highlights from the 2004 San Antonio Breast Cancer Symposium", Schaumburg, IL, March 2, 2005.
101. Participated, along with Dr. Edith A. Perez, in a Hem/Onc fellows breast case conference, The University of Oklahoma, College of Medicine, Oklahoma City, OK, February 11, 2005.
102. Invited Speaker, "San Antonio Update in Adjuvant and Neoadjuvant Therapy" 2nd Annual Breast Conference, The University of Oklahoma, College of Medicine, Oklahoma City, OK, February 10, 2005.
103. Invited Speaker, "Clinical Applications: Highlights from the 2004 San Antonio Breast Cancer Symposium", Carol G. Simon Cancer Center, Morristown, NJ, February 5, 2005.
104. Invited Speaker, "Neoadjuvant Treatment for Metastatic Breast Cancer", an overview to education managers training class, Aventis Oncology, Bridgewater, NJ, November 15, 2004.
105. Invited Speaker, "New Treatments for Women Living with Advanced Breast Cancer", Hope on the Horizon: Living Beyond Breast Cancer's Stacy Goldstein Symposium on Breast Cancer. Somerset, NJ, October 30, 2004.
106. Invited Speaker, "Management of Bone Health Following Adjuvant Breast Cancer Treatment," 3rd Annual Conference, Update in Internal Medicine, Atlantic City, NJ, October 15, 2004.
107. Invited Speaker, "The Role of Aromatase Inhibitors in the Adjuvant Setting, Pfizer Pharmaceuticals, Philadelphia, PA, June 17, 2004.
108. Invited Speaker, "Advances in the Neoadjuvant treatment of Breast Cancer", Somerset Medical Center, Somerville, NJ, June 3, 2004.
109. Invited Speaker, "Rapid Bone Loss and Fracture Risk in Breast and Prostate Cancer Patients", Novartis Pharmaceutical Corporation, Florham Park, NJ, May 25, 2004.
110. Invited Speaker, "Cancer Treatment Induced Bone Loss in Breast and Prostate Cancer Patients", Bisphosphonates Consultant Meeting, Novartis Pharmaceutical Corporation, Florham Park, NJ, May 21, 2004.
111. Invited Speaker, "Role of Genetics in Oncology", JFK Medical Center, Edison, NJ, May 20, 2004.

112. Invited Speaker, "Role of Femora in the Metastatic Setting", The North American Education Network on Aromatase Inhibition Faculty Curriculum Development Workshop, Novartis Oncology, Washington, DC, April 2-4, 2004.
113. Invited Speaker, "Adjuvant Treatment of Early Breast Cancer", Post San Antonio Discussion, Morristown Memorial Hospital, Morristown, NJ, February 28, 2004.
114. Invited Speaker, "Advances in the Neoadjuvant treatment of Breast Cancer" Overlook Hospital, Summit, NJ, February 27, 2004.
115. Invited Speaker, "Hope on the Horizon: New Treatment Options for Women With Advanced Breast Cancer", 4th Annual Conference for Young Women Affected by Breast Cancer, Young Survival Coalition, Philadelphia, PA, February 21, 2004.
116. International Invited Speaker, "Impact of Aromatase Inhibitors on Bone Loss in Cancer Patients", Physicians Education Resource, The 2nd Annual Future of Supportive Therapy in Oncology: An International Congress, St. Kitts, Caribbean, February 6, 2004.
117. International Invited Speaker, "Management of Bone Disease in Breast Cancer", Physicians Education Resource, The 2nd Annual Future of Supportive Therapy in Oncology: An International Congress, St. Kitts, Caribbean, February 6, 2004.
118. Invited Speaker, "Advances in the Neoadjuvant Treatment of Breast Cancer", Oncology Grand Rounds, Montefiore Medical Center, NY, January 15, 2004.
119. Invited Speaker, "Cancer Genetics", Medical Grand Rounds, Raritan Bay Medical Center, Perth Amboy, NJ, December 16, 2003.
120. Invited Speaker, "New Medical Directions in Breast Cancer Treatment: Where We've Been and Where We're Going", JFK Medical Center, Edison, NJ, December 11, 2003.
121. Invited Speaker, "Breast Cancer: Risk factors, and Prevention", Merck & Co., Inc. Rahway, NJ, October 15, 2003.
122. Invited Speaker, "Overview of Breast Cancer", Oncology Nursing Fundamentals course, Robert Wood Johnson University Hospital, New Brunswick, NJ, July 8, 2003.
123. Invited Speaker, NJHA (New Jersey Hospital Association), "Breast Cancer Epidemiology, Early Detection and Prevention". Princeton, NJ, June 24, 2003.
124. Presented to ACE INA the "Life Center" concept for their June Breast Cancer Education Series. Philadelphia, PA. (Toppmeyer), June 20, 2003.
125. Invited Participant for an Editorial Advisory Board for the Breast Cancer Update audio series. Dr. Neil Love, New York, NY, May 16-17, 2003.
126. Invited Participant in the NOCR (Network for Oncology Communication & Research) Breast Cancer Speaker Training Workshop. Palm Beach, Florida., May 9-10, 2003.
127. Invited Participant, "The Governor's Conference on Effective Partnering in Cancer Research", William N. Hait, M.D., Ph.D. and Governor James E. McGreevey. Absecon, NJ, April 27-29, 2003.
128. Invited Participant Roundtable Panel, "Assessment and Measurement of Quality of Life in Cancer Care". New Jersey Commission on Cancer Research. West Orange, NJ, April 9, 2003.
129. Participated in a Round Table discussion, "Where would you use anthracyclines, alkylating agents, taxanes, or hormonal therapy"? Aventis Oncology. Bridgewater, NJ, April 7, 2003.
130. Invited consultant for Aventis Oncology Medical Affairs. "Aventis Oncology on Taxotere for Injection Concentrate for Early Stage Breast Cancer". Newark, NJ, March 27, 2003.
131. Invited Speaker, Grand Rounds at Bayshore Hospital, "The Role of Taxanes in Metastatic Breast Cancer". Holmdel, NJ, March 14, 2003.
132. Invited speaker, "Adjuvant treatment for hormone receptor-positive premenopausal breast cancer". Princeton, NJ, February 5, 2003.
133. Invited participant for Roche Pharmaceuticals' oncology patient education program, "The Cancer Companion Series." Scottsdale, Arizona, January 31-February 2, 2003.

134. Lectured at Medical Grand Round, "Breast Cancer: Update 2003", Mountainside Hospital. Montclair, NJ, January 30, 2003.
135. Invited consultant for NOCR (Network for Oncology Communication & Research), to discuss the San Antonio Breast Cancer Highlights meeting. New York, NY, January 24, 2003.
136. Invited by Neil Love, MD, Editor, Breast Cancer Update, to participate in a medical oncologist panel, "Optimal Utilization of Chemotherapy in Management of Women with Metastatic Breast Cancer". The 25th Annual San Antonio Breast Cancer Symposium. San Antonio, Texas, December 13, 2002.
137. Invited Speaker, for the Department of Defense Breast Cancer Research Program meeting entitled "Era of Hope". Title: "The Impact of Genetics on the Development of Pre-Menopausal Breast Cancer", Orlando, Florida, September 27, 2002.
138. Presented at Saint James Hospital, Continuing Medical Education Conference, Grand Rounds, "Cancer Genetics", Newark, NJ, September 25, 2002.
139. Participated on the Novartis Executive Breast Cancer Advisory Council. Panico's Restaurant, New Brunswick, NJ, September 9, 2002.
140. Invited Speaker, "Hormonal Therapies in Breast Cancer: New Data". Lansdowne Resort, Lansdowne, Virginia (sponsored by Novartis), June 8, 2001.
141. Invited Speaker, "The STAR Trial – Breast Cancer Prevention", Honeywell Headquarters, Morris Township, NJ, May 31, 2001.
142. Two Poster presentations at the ASCO 2001 Annual Meeting. San Francisco, CA, May 9, 2001.
143. Presenter at the CINJ Annual Retreat. Princeton, NJ. See Abstract, April 25, 2001.
144. Invited Speaker, "Basic Cancer Genetics for Healthcare Providers: Risks and Realities". 2nd Annual New Jersey Physicians Conference, Atlantic City, NJ, April 20, 2001.
145. Invited Speaker, "Advances in the Treatment of Metastatic Breast Cancer". Cirque Du Soliel's, Liberty State Park, Jersey City, NJ. (Aventis Oncology), April, 18, 2001.
146. Invited speaker, "Cancer Genetics: Risk and Assessment", Grand Rounds, The Medical Center At Princeton, April 3, 2001.
147. Invited speaker, "Femara in Advanced Breast Cancer", Phoenix, Arizona, March 23, 2001.
148. VIP Speakers Forum, "Femara-New Hormonal Treatment in Breast Cancer", Mercer County Medical Center, March 2, 2001.
149. Invited Lecturer at the FEMARA Clinical Consultants Forum. Pinehurst, NC, March 16, 2001.
150. "Cancer Genetics for the Health Care Professional". Vineland Developmental Center, Vineland, NJ, March 12, 2001.
151. Grand Rounds Presenter at Somerset Medical Center. Topic: Genetic Testing for Breast, Ovarian and Colon Cancer. CME 1 hr, March 1, 2001.
152. "ECOG Update and Breast Cancer", Mountainside Hospital, February 14, 2001.
153. "Cancer Genetics and Risk Management", Oncology Grand Rounds, Mountainside Hospital, Montclair, NJ, February 13, 2001.
154. Lecture "Genetics The Future is Now". 2nd year medical students, Main Lecture Hall, RWJMS, Piscataway, NJ, December 13, 2000.
155. Invited Speaker, "New Paradigms in Hormonal Therapy for Breast Cancer", Bayonne Hospital, Bayonne, NJ, November 15, 2000.
156. Keynote Speaker, "Tamoxifen: Breast Cancer Prevention", at The Breast Cancer Symposium, Saint Peter's University Hospital organized by the UMDNJ RWJUH Residents, November 3, 2000.
157. Invited Speaker, "Familial Breast and Ovarian Cancer Education Seminar", at The Cancer Institute of New Jersey, October 26, 2000.
158. Invited speaker, "Emerging New Therapies In The Treatment Of Breast Cancer", Kimball Medical Center, NJ, October 24, 2000.
159. Invited speaker "Breast Cancer Adjuvant Therapy," Novartis in East Hanover, NJ, August 31, 2000.

160. Invited Speaker, "Breast Cancer and Genetics from Laboratory to Clinical Setting, Jersey Shore Medical Center, November 2, 1999.
161. "Breast Cancer Prevention," RWJ UH Grand Rounds, New Brunswick, NJ, October 27, 1999.
162. "Current Management of Breast Cancer" East Tennessee State University, 10/20/99.
163. Invited Speaker, "Breast Cancer Prevention Trials" Raritan Bay Medical Center, Wilentz Lecture, Perth Amboy, New Jersey, October 26, 1999.
164. Presenter at CINJ's annual retreat Plenary session, 5/28/99
165. Invited Speaker, "Cancer Screening for the general Gynecological practice". 49th Annual Meeting - New Jersey Obstetrical & Gynecological Society, June 6, 1997.
166. Invited Speaker, Breast Health Forum Presentation - "Breast Cancer Risk Factors and Screening" – Rahway Hospital, Rahway, September 29, 1996.
167. Invited Speaker, Hackensack Hospital "Transitional Research and Pharmacokinetics" – Hackensack, September, 16, 1996.